###begin article-title 0
###xml 44 50 <span type="species:ncbi:9606">Humans</span>
A Compartment Model of VEGF Distribution in Humans in the Presence of Soluble VEGF Receptor-1 Acting as a Ligand Trap
###end article-title 0
###begin p 1
Conceived and designed the experiments: FTHW MOS FMG ASP. Performed the experiments: FTHW. Analyzed the data: FTHW MOS FMG ASP. Wrote the paper: FTHW MOS FMG ASP.
###end p 1
###begin p 2
###xml 1359 1362 1359 1362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1371 1374 1371 1374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1166 1171 <span type="species:ncbi:9606">human</span>
###xml 1533 1538 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor (VEGF), through its activation of cell surface receptor tyrosine kinases including VEGFR1 and VEGFR2, is a vital regulator of stimulatory and inhibitory processes that keep angiogenesis - new capillary growth from existing microvasculature - at a dynamic balance in normal physiology. Soluble VEGF receptor-1 (sVEGFR1) - a naturally-occurring truncated version of VEGFR1 lacking the transmembrane and intracellular signaling domains - has been postulated to exert inhibitory effects on angiogenic signaling via two mechanisms: direct sequestration of angiogenic ligands such as VEGF; or dominant-negative heterodimerization with surface VEGFRs. In pre-clinical studies, sVEGFR1 gene and protein therapy have demonstrated efficacy in inhibiting tumor angiogenesis; while in clinical studies, sVEGFR1 has shown utility as a diagnostic or prognostic marker in a widening array of angiogenesis-dependent diseases. Here we developed a novel computational multi-tissue model for recapitulating the dynamic systemic distributions of VEGF and sVEGFR1. Model features included: physiologically-based multi-scale compartmentalization of the human body; inter-compartmental macromolecular biotransport processes (vascular permeability, lymphatic drainage); and molecularly-detailed binding interactions between the ligand isoforms VEGF121 and VEGF165, signaling receptors VEGFR1 and VEGFR2, non-signaling co-receptor neuropilin-1 (NRP1), as well as sVEGFR1. The model was parameterized to represent a healthy human subject, whereupon we investigated the effects of sVEGFR1 on the distribution and activation of VEGF ligands and receptors. We assessed the healthy baseline stability of circulating VEGF and sVEGFR1 levels in plasma, as well as their reliability in indicating tissue-level angiogenic signaling potential. Unexpectedly, simulated results showed that sVEGFR1 - acting as a diffusible VEGF sink alone, i.e., without sVEGFR1-VEGFR heterodimerization - did not significantly lower interstitial VEGF, nor inhibit signaling potential in tissues. Additionally, the sensitivity of plasma VEGF and sVEGFR1 to physiological fluctuations in transport rates may partially account for the heterogeneity in clinical measurements of these circulating angiogenic markers, potentially hindering their diagnostic reliability for diseases.
###end p 2
###begin title 3
Introduction
###end title 3
###begin title 4
The VEGF System in Angiogenesis
###end title 4
###begin p 5
###xml 371 374 371 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-YlaHerttuala1">[1]</xref>
###xml 375 378 375 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann1">[3]</xref>
###xml 384 387 384 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 393 396 393 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 402 405 402 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 598 601 598 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gustafsson1">[4]</xref>
###xml 618 621 618 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">120</sub>
###xml 626 629 626 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 634 637 634 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sub>
###xml 647 650 647 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ng1">[5]</xref>
###xml 690 693 690 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 702 705 702 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 861 864 861 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-YlaHerttuala1">[1]</xref>
###xml 866 869 866 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Collinson1">[6]</xref>
###xml 920 923 920 923 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 987 990 987 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 999 1002 999 1002 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 1527 1530 1527 1530 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1530 1533 1530 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann2">[7]</xref>
###xml 464 469 <span type="species:ncbi:9606">human</span>
###xml 591 597 <span type="species:ncbi:9606">humans</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 1294 1299 <span type="species:ncbi:10090">mouse</span>
###xml 1307 1312 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor (VEGF) - a family of cytokines that include VEGF-A, VEGF-B and placental growth factor, PlGF - is central to the regulation of competing stimulatory and inhibitory biochemical reactions that keep vascular angiogenesis - the growth of new blood capillaries from existing microvasculature - at a critical homeostasis in normal physiology [1]-[3]. VEGF121, VEGF165, VEGF189 are considered the predominant pro-angiogenic isoforms of human VEGF-A (UniProt accession P15692); their mRNA expression levels in muscle tissues have been found to range from 3:4:3 in humans [4] to 8:77:15 (VEGF120:VEGF164:VEGF188) in mice [5]. Their endogenous prevalence makes VEGF121 and VEGF165 common therapeutic agents in pro-angiogenic treatment for ischemic pathologies such as peripheral arterial disease (PAD) and coronary artery disease (CAD) [1], [6]. Once secreted into the extracellular matrix, VEGF121 is generally considered a freely diffusible isoform, while VEGF165 and VEGF189 can be sequestered through its heparin-binding domain at interstitial and cell surface proteoglycans in significant quantities. Among the major endothelial cell surface receptor targets for these VEGF isoforms are: the tyrosine kinases VEGFR1 (Flt-1; UniProt accession P17948-1) and VEGFR2 (mouse Flk-1; human KDR; UniProt accession P35968); as well as the co-receptor neuropilin-1 (NRP1; UniProt accession O14786), which couples directly with VEGFR1, and indirectly with VEGFR2 through non-overlapping binding sites on VEGF165[7].
###end p 5
###begin title 6
Soluble VEGF Receptor-1
###end title 6
###begin p 7
###xml 213 216 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hornig1">[8]</xref>
###xml 218 221 218 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ahmad1">[9]</xref>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kendall1">[10]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Cai1">[12]</xref>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Barleon1">[13]</xref>
###xml 786 790 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-CebeSuarez1">[15]</xref>
Soluble VEGFR1 (sVEGFR1; UniProt accession P17948-2), also known as soluble fms-like tyrosine kinase receptor-1 (sFlt-1), is a naturally-occurring truncated 110-kDa version of the 180-kDa membrane-spanning VEGFR1 [8], [9], derived predominantly from alternative splicing of the VEGFR1 gene, but possibly with contributions from proteolytic shedding of the extracellular fragment of VEGFR1 as well [10]-[12]. While lacking the transmembrane and intracellular signaling domains of VEGFR1, sVEGFR1 retains the protein structure and molecular functionality of the first six immunoglobulin-like extracellular domains of VEGFR1: i.e., an affinity for VEGF ligands, the NRP1 co-receptor, and extracellular heparan sulfate proteoglycans, as well as a capacity for homo/hetero-dimerization [13]-[15].
###end p 7
###begin p 8
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ambati1">[16]</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Karumanchi1">[17]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Luttun1">[18]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hazarika1">[19]</xref>
###xml 842 845 842 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Collinson1">[6]</xref>
###xml 329 334 <span type="species:ncbi:10090">mouse</span>
###xml 598 606 <span type="species:ncbi:9606">patients</span>
Studies have shown that the anti-angiogenic property of sVEGFR1 plays a critical role in the normal physiology of maintaining corneal avascularity [16] and in the pathology of the pregnancy disorder, pre-eclampsia [17], [18]. Recently, sVEGFR1 has been implicated in the impaired ischemic muscle angiogenesis of PAD. In diabetic mouse models of PAD, muscle expression of VEGF and sVEGFR1 both increased after surgically-induced hindlimb ischemia [19]. In clinical trials of therapeutic angiogenesis for CAD and PAD, the inconsistent efficacy of VEGF protein/gene therapy prompted a hypothesis that patients of these atherosclerotic vascular diseases may suffer from ligand insensitivity due to impaired receptor signaling or altered expression of antagonists (e.g., sVEGFR1), rather than simply a lack of angiogenic growth factors themselves [6].
###end p 8
###begin p 9
###xml 232 235 232 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ahmad1">[9]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kendall2">[20]</xref>
###xml 291 298 291 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kommareddy1">[21]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ye1">[30]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Rota1">[31]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gehlbach1">[32]</xref>
###xml 556 560 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Afuwape1">[33]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Miotla1">[35]</xref>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kumai1">[36]</xref>
It has been postulated that sVEGFR1 inhibits VEGF-signaling via two molecular mechanisms - (1) direct ligand trapping of VEGF ligands; and (2) heterodimerization with surface VEGFR monomers to form dominant-negative receptor dimers [9], [20] - though their relative functional contributions in vivo are not known. Nonetheless, pre-clinical studies on sVEGFR1 gene/protein therapy have already shown success in interfering with VEGF-dependent pathological processes including tumor angiogenesis [21]-[30], ocular neovascularization [31], [32], inflammation [33]-[35] and edema [36].
###end p 9
###begin p 10
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Lamszus1">[37]</xref>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Bando1">[38]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aref1">[39]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Shapiro1">[40]</xref>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Woolcock1">[41]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Diab1">[42]</xref>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Findley1">[43]</xref>
###xml 581 585 581 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Findley1">[43]</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Makin1">[46]</xref>
###xml 874 878 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aref1">[39]</xref>
###xml 880 884 880 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Shapiro1">[40]</xref>
###xml 886 890 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Diab1">[42]</xref>
###xml 891 895 891 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Chung1">[52]</xref>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Blann1">[44]</xref>
###xml 1118 1122 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Widmer1">[53]</xref>
Furthermore, researchers are increasingly finding clinical utility for sVEGFR1, either independently or in combination with circulating VEGF or PlGF, as diagnostic and prognostic markers for a diversity of angiogenesis-dependent medical conditions: from astrocytic gliomas [37], primary breast cancer [38], acute myeloid leukemia [39], to sepsis [40], and pre-eclampsia [41], [42]. In PAD, while plasma VEGF has been correlated with disease severity [43], there is contradicting evidence regarding whether plasma sVEGFR1 level is significantly lowered relative to healthy controls [43]-[46]. A key issue hindering the reliability of circulating sVEGFR1 levels as surrogate markers of the angiogenic status in angiogenesis-dependent pathologies is the striking inter-study and intra-study heterogeneity in clinical measurements of plasma sVEGFR1 for healthy control subjects [39], [40], [42]-[52] - a variability of over several orders of magnitude which may be attributable to inter-study methodological differences, as well as natural variation at physiological baseline among individuals within control groups [44], [53].
###end p 10
###begin p 11
###xml 154 159 <span type="species:ncbi:9606">human</span>
Hence we identified the need for a computational model that predicts the systemic distributions and molecular interactions of VEGF and sVEGFR1 across the human body, to serve as a platform for the mechanistic study of sVEGFR1's purported anti-angiogenic properties, as well as the pre-clinical study of sVEGFR1 as a disease marker and therapeutic agent.
###end p 11
###begin title 12
Computational Systems Biology Modeling
###end title 12
###begin p 13
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 110 113 110 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 119 122 119 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann4">[55]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ji1">[58]</xref>
###xml 820 824 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Stefanini1">[59]</xref>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 441 444 <span type="species:ncbi:10116">rat</span>
###xml 630 635 <span type="species:ncbi:9606">human</span>
###xml 671 676 <span type="species:ncbi:9606">human</span>
We have previously developed several computational models of the in vivo biochemical interactions between VEGF121, VEGF165, VEGFR1, VEGFR2, NRP1, and the interstitial matrix in skeletal muscle, including: a spatially-averaged single-tissue model of the human vastus lateralis muscle at rest [54]; and several 3D models for predicting spatial molecular gradients and intra-muscular pro-angiogenic treatment outcomes in resting and exercising rat extensor digitorum longus muscle [55]-[58]. A recent extension has been to develop a multi-tissue lumped-compartment framework to describe the systemic distributions of VEGF across the human body; a first application to study human breast cancer introduced macromolecular transport between the blood, healthy solid tissue and tumor compartments through vascular permeability [59]. In the present study, further model extensions have been made to include: (i) sVEGFR1, an endogenous antagonist of VEGF, into the network of molecular interactions; as well as (ii) lymphatic drainage, as a second mode of macromolecular transport from the solid tissue compartments into the blood.
###end p 13
###begin title 14
Lymphatic Drainage of sVEGFR1
###end title 14
###begin p 15
###xml 142 146 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Alitalo1">[60]</xref>
###xml 323 327 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kendall1">[10]</xref>
###xml 366 369 342 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hornig1">[8]</xref>
###xml 907 911 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Havas1">[61]</xref>
###xml 913 917 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aukland1">[62]</xref>
###xml 1625 1629 1601 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aukland1">[62]</xref>
###xml 1680 1684 1656 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Blann1">[44]</xref>
###xml 1686 1690 1662 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Belgore1">[45]</xref>
###xml 1871 1875 1847 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Havas1">[61]</xref>
###xml 1877 1881 1853 1857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Regensteiner1">[63]</xref>
###xml 1883 1887 1859 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Havas2">[64]</xref>
###xml 1756 1764 <span type="species:ncbi:9606">patients</span>
The lymphatic vasculature is a one-way drainage system that returns fluid and proteins from the interstitial spaces of tissues into the blood [60]. The inclusion of lymphatic drainage in the modeling of sVEGFR1 biodistribution was particularly relevant for two reasons. Firstly, relative to VEGF (approximately46-kDa dimer [10]), sVEGFR1 (approximately220-kDa dimer [8]) is expected to rely more on lymphatic drainage to clear its interstitial accumulation, because its larger molecular size theoretically should hinder blood capillary reabsorption (vascular permeability), and it also has relatively fewer routes of receptor-mediated internalization (especially if heterodimerization with surface receptors proves insignificant). Secondly, the lymphatic capillaries in skeletal muscle rely on the "milking effect" of rhythmical contractions and relaxations by adjacent skeletal muscle for lymph propulsion [61], [62]. As lymph flow directly transfers protein mass from the interstitial space into the blood, concentrations of VEGF and sVEGFR1 in muscle interstitia and in plasma could be sensitive to the muscle activity-dependent changes in lymph flow rates. Hence we hypothesized that the physiological activity-dependent fluctuations in lymphatic drainage rates may contribute to the clinical heterogeneity observed in plasma measurements of VEGF and sVEGFR1. The implications of such an association would be significant: (i) impaired ambulation (due to the PAD symptoms of intermittent claudication) and the associated reductions in leg muscle contractions and lymph flow rate may partially account for the tissue edema [62] and lowered plasma sVEGFR1 levels observed in PAD [44], [45]; conversely, (ii) the success of exercise rehabilitation for PAD patients can potentially be explained by the restoration of lymph flow rate with increased leg muscle contractions [61], [63], [64].
###end p 15
###begin title 16
Objectives and Achievements
###end title 16
###begin p 17
###xml 203 208 <span type="species:ncbi:9606">human</span>
In summary, the goals of this study were: (1) to develop a computational multi-tissue model for recapitulating the systemic distributions of VEGF and sVEGFR1; (2) to parameterize the model for a healthy human subject; and (3) to investigate the effects of sVEGFR1 and lymphatic drainage on the VEGF ligand-receptor system. Firstly, we explored whether sVEGFR1 - in its capacity as a VEGF sink alone (without heterodimerization with surface VEGFRs) - can demonstrate anti-angiogenic potential, e.g., lowering free VEGF availability and inhibiting signaling complex formation. Secondly, we tested the hypothesis that physiological fluctuations in transport rates - especially the muscle activity-dependent lymphatic drainage rates - contribute to the natural variability in plasma concentrations of VEGF and sVEGFR1 as observed clinically. Taken together, the results yielded an assessment of the general utility of plasma VEGF and sVEGFR1 levels as surrogate markers for the angiogenic status in diseases, specifically regarding their stability (i.e., whether their healthy benchmark levels remained steady throughout physiological perturbations in system parameters including transport rates) and reliability (i.e., whether their changes correlated with interstitial changes in angiogenic signaling potential).
###end p 17
###begin title 18
Materials and Methods
###end title 18
###begin title 19
1. Compartmental Model Formulation
###end title 19
###begin p 20
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">calf</italic>
###xml 282 307 282 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">normal (rest of the body)</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">blood</italic>
###xml 792 796 792 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Findley1">[43]</xref>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Norgren1">[65]</xref>
###xml 1080 1087 1080 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1A</xref>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 214 218 <span type="species:ncbi:9913">calf</span>
###xml 450 454 <span type="species:ncbi:9913">calf</span>
###xml 543 547 <span type="species:ncbi:9913">calf</span>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
###xml 705 709 <span type="species:ncbi:9913">calf</span>
###xml 1138 1143 <span type="species:ncbi:9606">human</span>
To model the systemic distributions of VEGF and sVEGFR1 associated with healthy subjects, a physiologically-based pharmacokinetic model was constructed that divided the human body into three compartments: (1) the "calf", consisting of the gastrocnemius and soleus muscles; (2) the "normal (rest of the body)", consisting of all other solid tissues; and (3) the "blood", that interacts with the other two compartments. The purpose of distinguishing a calf compartment was two-fold: (a) to investigate the differential effects of varying local (calf) vs. global (body) parameters in the present study; and (b) in preparation for future modelling of and comparative investigations against PAD patients whose calf muscles are common symptomatic sites of tissue ischemia and impaired angiogenesis [43], [65]). Further spatial distinctions within the tissue compartments into parenchymal space, interstitial space and capillary space were necessary to distinguish tissue-specific pools of VEGF and sVEGFR1 into free vs. matrix-bound vs. receptor-bound subpopulations. As illustrated in Fig. 1A, histological data from cross-sections of healthy human muscles were used to characterize the relevant volumes and surface areas of these spatial subdivisions for the tissue compartments.
###end p 20
###begin title 21
Schematic of Multi-Tissue Model of VEGF and sVEGFR1 Distributions.
###end title 21
###begin p 22
###xml 3 130 3 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Whole-body compartmentalization of solid tissues into &#8216;Calf&#8217; vs. &#8216;Normal&#8217; (rest of the body) compartments for a healthy subject</italic>
###xml 714 720 714 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 816 854 816 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mass flows through 3-compartment model</italic>
###xml 1252 1255 1252 1255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1270 1273 1270 1273 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1217 1471 1217 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Molecular Interactions between VEGF<sub>121</sub> (yellow), VEGF<sub>165</sub> (blue), sVEGFR1 (orange), interstitial matrix binding sites (glycosaminoglycans or &#8220;GAG&#8221;; purple), and the abluminal endothelial cell surface receptors VEGFR1 (red), VEGFR2 (blue), and NRP1 (green)</italic>
###xml 1533 1536 1533 1536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1551 1554 1551 1554 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1610 1613 1610 1613 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1666 1669 1666 1669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 2153 2208 2153 2208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Protein domains of full-length vs. soluble human VEGFR1</italic>
###xml 58 62 <span type="species:ncbi:9913">Calf</span>
###xml 469 474 <span type="species:ncbi:9606">human</span>
###xml 566 569 <span type="species:ncbi:9606">man</span>
###xml 2196 2201 <span type="species:ncbi:9606">human</span>
A. Whole-body compartmentalization of solid tissues into 'Calf' vs. 'Normal' (rest of the body) compartments for a healthy subject. Characteristic geometries - parenchymal cell (grayish red), interstitial space (green/blue) and capillary space (endothelial cells (EC) in yellow, plasma in pink, red blood cells (RBC) in red) volume fractions; basement membrane (BM) thicknesses; and EC surface areas - were quantified from histological cross-sections of representative human skeletal muscles (gastrocnemius and vastus lateralis). Illustrations adapted from: 'muscle man' series from Andreas Vesalius, De Humani Corpis Fabrica, 1543, courtesy of the National Library of Medicine; histological micrographs from Baum et al. J Vasc Res 2007;44:202-213. Note: BM thicknesses and molecule sizes are not drawn to scale. B. Mass flows through 3-compartment model. VEGF and sVEGFR1 were secreted from parenchymal and endothelial cell sources respectively. Both were internalized upon binding with abluminal endothelial surface receptors. All soluble species were subjected to lymphatic drainage from interstitial space into the blood, bidirectional permeability through the endothelia, and direct clearance from the blood. C. Molecular Interactions between VEGF121 (yellow), VEGF165 (blue), sVEGFR1 (orange), interstitial matrix binding sites (glycosaminoglycans or "GAG"; purple), and the abluminal endothelial cell surface receptors VEGFR1 (red), VEGFR2 (blue), and NRP1 (green). The sVEGFR1 interactions modeled were: trapping of free VEGF121 (T1a) and VEGF165 (T2); giving NRP1s an indirect way of sequestering VEGF121 to the cell surface (T1b or T3); and displacing VEGF165 from interstitial matrix sites (D1b) through competitive binding (D1a). This model neglected sVEGFR1-heterodimerization with surface VEGFRs, thus ignoring the possible effect of sVEGFR1 in lowering the effective density of functional surface VEGFRs. Hence in this study, any effect that the presence of sVEGFR1 had on VEGF-signaling potential (i.e, the formation of VEGF-VEGFR complexes) resulted from sVEGFR1's influence on the effective concentration of interstitial free VEGF. D. Protein domains of full-length vs. soluble human VEGFR1. sVEGFR1's binding affinities for the VEGF ligand, interstitial matrix sites (e.g., heparan sulfate proteoglycans) and NRP1 were inferred from the identical first 6 immunoglobulin-like domains of the full-length VEGFR1.
###end p 22
###begin p 23
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 53 56 53 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 205 208 205 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">120</sub>
###xml 244 247 244 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 252 255 252 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sub>
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ng1">[5]</xref>
###xml 360 367 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1B</xref>
###xml 712 715 712 715 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Maharaj1">[66]</xref>
###xml 873 880 873 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1C</xref>
###xml 1458 1465 1458 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1D</xref>
###xml 1776 1785 1776 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1B,C</xref>
###xml 2123 2130 2123 2130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1B</xref>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
Within the tissue compartments, free VEGF121 and VEGF165 were secreted from parenchymal cells (myocytes) in a 1:10 ratio in correspondence with the mRNA expression ratio of freely diffusible isoforms (VEGF120) vs. heparin-binding isoforms (VEGF164+VEGF188) in mice [5]. Free sVEGFR1 was secreted abluminally from endothelial cells into the interstitial space (Fig. 1B); luminal secretion of sVEGFR1 was neglected in congruency with model assumptions to neglect luminal insertion of membrane-tethered VEGFRs (for which there is little quantitive evidence and will be separately investigated in further studies). Proteolytic shedding of sVEGFR1 from abluminal surface VEGFR1 was neglected in our model, as was VEGF165 proteolysis by plasmin and MMPs [66]. Tissue concentrations of VEGF and sVEGFR1 were then distributed - through competing binding interactions summarized in Fig. 1C - over three populations: (i) diffusing freely or as VEGF-sVEGFR1 complexes within the available interstitial fluid; (ii) sequestered in the endothelial basement membrane (EBM), extracellular matrix (ECM), and parenchymal basement membrane (PBM) regions of the interstitial space, each with distinct compositions of VEGF- and sVEGFR1-binding proteoglycans; or (iii) bound to abluminal endothelial cell surface receptors. The binding interactions of sVEGFR1, in particular, were inferred functionalities based on the first six Ig-like domains that it has in common with VEGFR1 (Fig. 1D). Since the current implementation neglected heterodimerization of sVEGFR1 with surface VEGFRs, internalization of sVEGFR1 from the endothelial surface could only occur through binding to surface NRP1s; while VEGF could be internalized through the six signaling VEGFR complexes in addition to uncoupled NRP1s (Fig. 1B,C). Additionally, the soluble volumetric species - free VEGF, free sVEGFR1 and VEGF-sVEGFR1 complex - were subjected to inter-compartmental transport processes: (i) lymphatic drainage from the interstitium into plasma; (ii) bidirectional vascular permeability between interstitial fluid and plasma; and (iii) direct clearance from plasma (Fig. 1B).
###end p 23
###begin p 24
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
In this spatially-averaged model, gradients of soluble species were neglected within the interstitial fluid (where diffusion time was faster than reaction time as justified by Damkohler number <1 [54]) and plasma. Spatial variability in matrix- or receptor- binding was also neglected.
###end p 24
###begin p 25
###xml 40 44 40 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann7">[67]</xref>
###xml 259 266 259 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 286 294 286 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Huang1">[68]</xref>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Neagoe1">[69]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann8">[70]</xref>
As in our previous compartmental models [54], [67], surface receptors were present only in pre-associated homodimeric form, i.e., the biophysical dynamics of VEGF-induced receptor dimerization and VEGFR1-VEGFR2 heterodimers were both ignored, for the lack of in vivo validation despite in vitro[68], [69] and theoretical evidence [70].
###end p 25
###begin p 26
###xml 9 17 9 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hornig1">[8]</xref>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kendall1">[10]</xref>
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 744 752 744 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1C:</xref>
Although in vitro studies had found sVEGFR1, in both monomeric and dimeric forms, to be able to form complexes with VEGF in significant amounts in HUVEC-conditioned media [8], [10], there is currently no in vivo data on their relative quantities or the dimerization mechanism (whether some sVEGFR1 are secreted as homodimers or whether dimerization is ligand-dependent). Thus in parallel to our surface receptors, sVEGFR1 was modeled as a uniform species of pre-associated homodimers as a first approximation. Furthermore, sVEGFR1-heterodimerization with surface VEGFRs (i.e., the association between monomeric sVEGFR1 and surface VEGFR monomers) was neglected in this first study to independently investigate sVEGFR1's VEGF-trapping function (Fig. 1C: interactions 'T1-3').
###end p 26
###begin title 27
2. Molecular Interactions & Transport Equations
###end title 27
###begin p 28
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 339 340 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</sub>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>j</sub></italic>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 348 349 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</sub>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>B</sub></italic>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</italic>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 483 484 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 485 489 485 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,j</sub>
###xml 485 489 485 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,j</sub></italic>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 497 499 497 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 497 499 497 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 653 654 653 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</italic>
###xml 957 961 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Stefanini1">[59]</xref>
###xml 963 967 963 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Truskey1">[71]</xref>
In the mathematical formulation of our model, a system of 61 coupled nonlinear ordinary differential equations (ODEs) was used to describe the temporal dependence of each molecular species' tissue and blood concentrations on their binding interactions and transport processes. Protein concentrations, when expressed in the notations of [X]j and [X]B, as in the ODEs below, are in units of "moles/cm3 of tissue j" and "moles/cm3 of blood" respectively. Elsewhere, separate notations [X]IS,j and [X]pl refer to these concentrations in units of M, as converted to their relevant fluid volume basis, i.e., "moles/L of available interstitial fluid in tissue j" and "moles/L of plasma" respectively. The "available" interstitial fluid volume excludes all interstitial fluid spaces that are inaccessible to molecules, including isolated pores (e.g., fluid spaces trapped during matrix deposition) and steric exclusion spaces near solid surfaces (e.g. bound water) [59], [71]. Conversions between the two sets of notations are as follows:and
###end p 28
###begin title 29
2.1 Tissue Equations
###end title 29
###begin p 30
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</italic>
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 49 53 <span type="species:ncbi:9913">Calf</span>
Each tissue compartment j = {N for Normal; D for Calf} contained 28 molecular species whose governing equations were as follows:
###end p 30
###begin title 31
i. Interstitial Matrix
###end title 31
###begin p 32
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 228 231 228 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 276 279 276 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 284 285 284 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 282 285 282 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR<sub>1</sub></italic>
###xml 336 338 336 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 335 338 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>on</sub></italic>
###xml 348 349 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 365 368 365 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">off</sub>
###xml 364 368 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>off</sub></italic>
###xml 371 373 371 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 498 501 498 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 569 572 569 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
The following 9 equations describe the occupancies of VEGF- and sVEGFR1-binding sites in the interstitial matrix. Here, [M] denotes the concentration of matrix binding sites in the ECM, EBM, or PBM as specified in subscripts; [V165] the interstitial concentration of free VEGF165; [sR1] the interstitial concentration of free sVEGFR1; kon (moles/cm3 tissue/s) and koff (s-1) are the kinetic rates for binding and unbinding respectively. The current model assumed the subsequent binding of free VEGF165 onto matrix-bound sVEGFR1 or of free sVEGFR1 onto matrix-bound VEGF165 to be negligible; no experimental data on these spatial configurations were available. The unconfirmed binding of VEGF-sVEGFR1 complexes directly onto unoccupied matrix sites was also neglected.
###end p 32
###begin title 33
ii. Abluminal Endothelial Cell Surface
###end title 33
###begin p 34
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 185 186 185 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 257 259 257 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VR</italic>
###xml 266 268 266 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VN</italic>
###xml 316 319 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RVN</italic>
###xml 326 329 326 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VRN</italic>
###xml 370 371 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>c</sub></italic>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 462 468 462 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dissoc</sub>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>dissoc</sub></italic>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 526 529 526 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sub>
###xml 525 529 525 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>int</sub></italic>
###xml 532 534 532 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 599 600 599 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sub>
###xml 598 600 598 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s<sub>R</sub></italic>
###xml 686 689 686 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sub>
###xml 685 689 685 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>int</sub></italic>
###xml 1079 1080 1079 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sub>
###xml 1078 1080 1078 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s<sub>R</sub></italic>
###xml 1084 1087 1084 1087 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sub>
###xml 1083 1087 1083 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>int</sub></italic>
###xml 1089 1090 1089 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1090 1095 1090 1095 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">total</sub>
###xml 1187 1190 1187 1190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1225 1227 1225 1227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 1224 1227 1224 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>on</sub></italic>
The next 14 equations describe the ligand-binding and co-receptor-coupling status of abluminal endothelial surface receptors. Notation for the densities of these surface species are: [R1], [R2] and [N1] for unoccupied VEGFR1, VEGFR2 and NRP1 respectively; [VR] and [VN] for VEGF-bound VEGFRs and NRP1 respectively; [RVN] and [VRN] for NRP1-coupled VEGF-ligated VEGFRs. kc (moles/cm3 tissue/s) denotes the coupling rate between a VEGFR and the co-receptor NRP1; kdissoc (s-1) denotes the direct decoupling of VEGFR1 and NRP1. kint (s-1) is the internalization rate of free or bound receptors; while sR is the insertion rate of free receptors back into the cell membrane. In this study, kint was assumed to be identical for all free receptors and complexes, though there is possibility for future investigation of differential internalization rates for phosphorylated and unphosphorylated receptors. There was also no feedback regulation of receptor expression as a function of VEGF signaling: i.e., constant total (free + occupied) receptor densities were maintained by defining sR = kint.[Rtotal]. Curly brackets contain the terms referring to the direct binding interaction between VEGF121 and NRP1, which were turned off (kon = 0) in the base case and tested during sensitivity analyses.
###end p 34
###begin title 35
iii. Interstitial Fluid
###end title 35
###begin p 36
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 190 191 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR<sub>1</sub></italic>
The next 5 equations govern the soluble species of the interstitial fluid, including the complexes formed between the VEGF isoforms and sVEGFR1, the concentrations of which are denoted [V.sR1].
###end p 36
###begin p 37
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sub>
###xml 54 56 54 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q<sub>V</sub></italic>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 181 184 181 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q<sub>sR1</sub></italic>
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sub>
###xml 497 499 497 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q<sub>V</sub></italic>
###xml 505 508 505 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q<sub>sR1</sub></italic>
###xml 639 646 639 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Free VEGF isoforms were secreted at constant rates of qV (moles/cm3 tissue/s) from myocytes; while free sVEGFR1 was secreted abluminally by endothelial cells at a constant rate of qsR1 (moles/cm3 tissue/s). The current implementation assumed no time-dependent feedback regulation on secretion rates as a function of VEGFR phosphorylation or internalization. In this study, the cell sources noted above were relevant only for unit conversion of the secretion rates to a "per cell" basis; i.e., the qV and qsR1 terms would have included endothelial or non-myocyte sources of VEGF and parenchymal sources of sVEGFR1 if these were significant in vivo.
###end p 37
###begin p 38
###xml 99 100 99 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 98 100 98 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 104 105 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 136 141 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B&#8594;j</italic>
###xml 145 150 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j&#8594;B</italic>
###xml 192 193 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 191 193 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 203 205 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">jB</sub>
###xml 202 205 198 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S<sub>jB</sub></italic>
###xml 209 210 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 316 317 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</italic>
###xml 392 399 384 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Methods</xref>
###xml 427 428 419 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</sub>
###xml 426 428 418 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U<sub>j</sub></italic>
###xml 434 436 426 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AV</sub>
###xml 433 436 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>AV</sub></italic>
All interstitial soluble species were subjected to lymphatic drainage into the blood at a rate of kL (cm3/s), as well as bidirectional (B-->j or j-->B) vascular permeability flow at rates of kP (cm/s). SjB (cm2), which denotes the total abluminal endothelial surface area exposed to the interstitial space of tissue j, and gamma, which is the endothelial surface area recruitment factor (see Methods section 3.3i), along with Uj and KAV, were geometric conversion factors that restrict the volumes of interstitial fluid and plasma accessible to macromolecular exchange.
###end p 38
###begin title 39
2.2. Blood Equations
###end title 39
###begin p 40
###xml 139 142 139 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,B</sub>
###xml 146 151 146 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,B</sub>
###xml 209 216 209 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Karumanchi1">[17]</xref>
###xml 494 496 494 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 493 496 493 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
###xml 499 501 499 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
The last 5 equations described the blood populations of the soluble species. There were no source terms in the blood for VEGF or sVEGFR1 (qV,B = qsR1,B = 0), although luminal secretion from the endothelium or in situ release from formed elements (e.g., platelets, monocytes [17]) could be explored in future implementations. In addition to the lymphatic and vascular permeability flows, the soluble species in plasma were subjected to a third transport process - direct clearance at a rate of kCL (s-1).
###end p 40
###begin title 41
###xml 40 45 <span type="species:ncbi:9606">Human</span>
3. Model Parameterization for a Healthy Human
###end title 41
###begin p 42
This section describes the parameterization of compartmental geometry, binding kinetic rates, biotransport rates, and protein expression levels necessary to solve the model system of ODEs.
###end p 42
###begin title 43
3.1. Geometry
###end title 43
###begin title 44
###xml 11 15 <span type="species:ncbi:9913">Calf</span>
i. Healthy Calf Muscle Compartment
###end title 44
###begin p 45
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Elliott1">[72]</xref>
###xml 255 262 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
###xml 12 16 <span type="species:ncbi:9913">calf</span>
###xml 234 239 <span type="species:ncbi:9606">human</span>
The healthy calf compartment was modeled with a control volume of 868 cm3 (unilateral gastrocnemius and soleus muscles) [72], and with the following histological parameters taken from gastrocnemius data of a typical sedentary healthy human, summarized in Table 1.
###end p 45
###begin title 46
Geometric Parameterization of Histological Cross-Sections.
###end title 46
###begin p 47
FCSA = fiber cross-sectional area.
###end p 47
###begin p 48
MDSA = myonuclear domain surface area.
###end p 48
###begin p 49
###xml 20 21 20 21 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</underline>
###xml 26 27 26 27 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 34 35 34 35 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</underline>
###xml 50 51 50 51 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</underline>
FSAV = total muscle fibre surface area per tissue volume.
###end p 49
###begin p 50
CCSA = capillary cross-sectional area (EC+lumen).
###end p 50
###begin p 51
ECSA = endothelial cell surface area.
###end p 51
###begin p 52
###xml 13 14 13 14 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</underline>
###xml 25 26 25 26 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 33 34 33 34 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</underline>
###xml 49 50 49 50 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</underline>
ESAV = total endothelium surface area per tissue volume.
###end p 52
###begin p 53
IS = interstitial space.
###end p 53
###begin p 54
IF = interstitial fluid.
###end p 54
###begin p 55
calculated.
###end p 55
###begin p 56
###xml 98 102 <span type="species:ncbi:9913">calf</span>
 = combined volume of lateral gastrocnemius, medial gastrocnemius, and soleus muscles (unilateral calf).
###end p 56
###begin p 57
 = approximated by collagen content.
###end p 57
###begin p 58
###xml 82 90 82 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1b</xref>
calculated for average partition coefficients of 0.85 in ECM and 0.325 in BM (see Table 1b).
###end p 58
###begin p 59
###xml 66 67 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 67 71 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-McGuigan1">[73]</xref>
###xml 216 220 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 324 328 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Allen1">[74]</xref>
###xml 449 453 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ohira1">[75]</xref>
###xml 512 513 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 578 579 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 651 652 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 704 708 688 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-McGuigan1">[73]</xref>
###xml 802 803 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 806 807 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 867 868 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 871 872 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
From the measured fiber cross-sectional area (FCSA) of 4173 microm2[73], the single muscle fiber was calculated to have a diameter of 73 microm and perimeter of 261 microm (non-cylindrical correction factor of 1.14) [54]. The myonuclear domain (MD) defines the cytoplasmic volume per nucleus within a multinucleated myocyte [74]. Assuming the gastrocnemius to have the same linear myonuclei density of 150 nuclei/mm as that measured from the soleus [75], the MD surface area was then calculated to be 1740 microm2/MD. Muscle fiber density (FD) was determined to be 199 fibers/mm2 tissue based on a reported capillary density (CD) of 231 capillaries/mm2 tissue and a capillary-to-fiber ratio (CF) of 1.16 [73]. This FD yielded a total muscle fiber surface area per unit volume of tissue (FSAV) of 520 cm2/cm3 tissue and a total muscle fiber volume fraction of 0.831 cm3/cm3 tissue.
###end p 59
###begin p 60
###xml 133 134 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 148 152 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Vracko1">[76]</xref>
###xml 370 374 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 576 577 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 580 581 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 598 599 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 602 603 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 715 716 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 772 776 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann9">[77]</xref>
###xml 810 814 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Levesque1">[78]</xref>
###xml 943 944 923 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 947 948 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 781 784 <span type="species:ncbi:9615">dog</span>
Capillaries of the lower leg were shown to have mean lumen, endothelium and total cross-sectional areas of 12.4, 11.6 and 24.0 microm2 respectively [76]. The corresponding luminal and abluminal capillary diameters were calculated to be 3.97 and 5.53 microm respectively, with an endothelium thickness of about 0.78 microm. A capillary perimeter correction factor of 1.1 [54] was assumed to give approximate luminal and abluminal perimeters of 13.7 and 19.1 microm respectively. Together with the mentioned CD, these values yielded a total capillary volume fraction of 0.006 cm3/cm3 tissue, 0.003 cm3/cm3 tissue of which was vascular space. The abluminal endothelial cell surface area (ECSA) was taken as 1000 microm2 per endothelial cell, averaged from hamster arteriolar [77] and dog aortic endothelial cells [78]; while the total abluminal endothelial surface area per tissue volume (ESAV) available for ligand-receptor binding came to 44 cm2/cm3 tissue.
###end p 60
###begin p 61
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Baum1">[79]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Vlodavsky1">[82]</xref>
###xml 591 595 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Levick1">[83]</xref>
###xml 741 742 741 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 745 746 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Levitt1">[84]</xref>
###xml 939 946 935 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t002">Table 2</xref>
###xml 1042 1046 1038 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Yuan1">[85]</xref>
###xml 1103 1107 1099 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Levick1">[83]</xref>
###xml 1122 1126 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Yuan1">[85]</xref>
###xml 1279 1283 1275 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Venturoli1">[86]</xref>
###xml 1338 1345 1334 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
###xml 143 147 <span type="species:ncbi:9913">calf</span>
As a result, the interstitial space (IS) left between muscle fibers and capillaries had a volume fraction of 0.163 cm3/cm3 tissue. The healthy calf IS volume comprised: 0.69% endothelial basement membrane (EBM) based on an average thickness of 254 nm [79]-[82]; 8.07% parenchymal basement membrane (PBM) assuming the same thickness as the EBM; and 91.24% extracellular matrix (ECM). Assuming collagen to be the major component in the IS by volume, the solid fraction of the ECM, EBM, PBM were taken as 13.4%, 45% and 45% respectively (dividing 14.175% collagen content in interstitial space [83] between BM and ECM volumes such that collagen density of BMs was triple that of ECM). The resulting fluid fraction of the interstitium - 0.137 cm3/cm3 tissue, consistent with measured range of 8 to 11% [84] - was in turn only fractionally available to permeable molecules depending on their partition coefficients (Phi). Species-specific Phi (Table 2) were extrapolated from theoretical calibration curves for dextran permeating through networks [85], using the appropriate network pore size (66 nm for ECM [83]; 7 nm for BMs [85]) and the corresponding hydraulic Stokes-Einstein radii between linear polydisperse dextran and globular VEGF-related proteins (conversion formulae from [86]). The final available fluid volumes are summarized in Table 1.
###end p 61
###begin title 62
Hydrodynamic Properties of Soluble Species.
###end title 62
###begin p 63
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 33 37 33 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Levick1">[83]</xref>
Assumed pore sizes of a 66 nm ECM[83].
###end p 63
###begin p 64
###xml 10 14 10 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Yuan1">[85]</xref>
7 nm in BM[85].
###end p 64
###begin title 65
ii. Normal (Rest of the body) Compartment
###end title 65
###begin p 66
###xml 183 184 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ward1">[87]</xref>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 285 291 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">normal</italic>
###xml 323 339 323 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rest of the body</italic>
###xml 376 377 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 27 30 <span type="species:ncbi:9606">man</span>
###xml 267 271 <span type="species:ncbi:9913">calf</span>
###xml 505 510 <span type="species:ncbi:9606">human</span>
###xml 766 770 <span type="species:ncbi:9913">calf</span>
The entire body of a 70 kg man minus the blood would weigh about 65 kg. As a first approximation, we modeled the entire 65 kg as homogenous skeletal muscle with a density of 1.06 g/cm3[87], giving a volume of 61,321 cm3. Subtracting from it the volume of the healthy calf muscle, the "normal" compartment representing the "rest of the body" was then determined to be 60,453 cm3. The following geometry parameters are slightly different from those we used previously [54], as these are taken directly from human vastus lateralis histological data, without the previous fitting requirements to match water spaces (1.4% vascular space and 7% interstitial fluid), nor previous adjustments based on theoretical oxygen consumptions. This was done for consistency with how calf compartment parameters were derived.
###end p 66
###begin p 67
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Andersen1">[88]</xref>
###xml 281 282 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 282 286 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Andersen1">[88]</xref>
###xml 341 342 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 381 382 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 442 443 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 446 447 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 596 597 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 776 780 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 844 848 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 936 937 910 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 988 989 962 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 992 993 966 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1053 1054 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1057 1058 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Muscle fiber density (FD) was determined to be 242 fibers/mm2 tissue based on a reported capillary density (CD) of 329 capillaries/mm2 tissue and a capillary-to-fiber ratio (CF) of 1.36 [88]. Muscle fiber cross-sectional area (FCSA) was experimentally measured at 4150+/-246 microm2[88]. Multiplying this measured average FCSA of 4150 microm2 and the calculated FD of 242 fibers/mm2 would have produced a theoretical impossibility - 1.0043 mm2/mm2 - reflecting overestimations in FCSA and/or FD. Thus the vastus lateralis FCSA was taken instead at one standard error below mean, i.e., 3904 microm2. From this conservative measurement of FCSA, the single muscle fiber was calculated to have a diameter of 71 microm and perimeter of 253 microm using a correction factor of 1.14 [54]. Keeping the assumed linear myonuclei density of 120 nuclei/mm [54], the surface area of the myonuclear domain (MD) was then recalculated to be 2104 microm2/MD. The new FD also yielded a total FSAV of 611 cm2/cm3 tissue and a total muscle fiber volume fraction of 0.944 cm3/cm3 tissue.
###end p 67
###begin p 68
###xml 152 156 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hernandez1">[89]</xref>
###xml 308 309 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 419 420 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 422 426 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Vracko1">[76]</xref>
###xml 491 495 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 670 671 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 674 675 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 692 693 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 696 697 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 781 782 753 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 786 790 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 917 918 889 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 921 922 893 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 820 824 <span type="species:ncbi:9913">calf</span>
The luminal and abluminal diameters of individual capillaries were taken from measurements in the vastus lateralis as 4.86 and 6.39 microm respectively [89]. From these, the endothelium thickness was calculated to be 0.77 microm, while the lumen and endothelium CSA were calculated to be 18.6 and 13.5 microm2 respectively, which agree with histological measurements from the mid-thigh (10.8+/-7.4 and 11.4+/-6.7 microm2) [76]. Assuming the same capillary perimeter correction factor of 1.1 [54], the luminal and abluminal perimeters were then 16.8 and 22.1 microm respectively. Together with the mentioned CD, these yielded a total capillary volume fraction of 0.011 cm3/cm3 tissue, 0.006 cm3/cm3 tissue of which was vascular space. Though the abluminal ECSA was still 1000 microm2/EC [54], a higher CD compared to the calf contributed to a higher abluminal endothelial surface area per tissue volume (ESAV) of 73 cm2/cm3 tissue in the normal compartment.
###end p 68
###begin p 69
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kalluri1">[90]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-McDonald1">[91]</xref>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Williamson1">[92]</xref>
###xml 415 422 415 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
Accordingly, the IS remaining between muscle fibers and capillaries had a volume fraction of 0.045 cm3/cm3 tissue. The normal compartment IS comprised: 1.41% EBM based on an average thickness of 87.5 nm [90], [91] (instead of the 43 nm previously taken [54] from extreme athletes to avoid extra exercise-trained effects [92]); 11.87% PBM assuming the same thickness as the EBM; and 86.72% ECM. As summarized in the Table 1, the available fluid fractions of each IS volume were calculated using the same solid fractions and Phi's as in healthy gastrocnemius.
###end p 69
###begin title 70
iii. Blood Compartment
###end title 70
###begin p 71
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Guyton1">[93]</xref>
Finally, the blood compartment was modeled with a volume of 5L, 60% of which was plasma [93]. Ultrastructures that were not explicitly modeled include the glycocalyx/cell-free layer or interendothelial clefts, the effects of which were incorporated within the transport parameters described below. Formed elements in the blood (e.g., platelets and leukocytes) were also ignored but could be considered as binding sites and/or sources for the soluble species in future model extensions.
###end p 71
###begin title 72
3.2. Binding and Coupling Kinetics
###end title 72
###begin p 73
###xml 63 70 63 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t003">Table 3</xref>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 369 370 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Autiero1">[94]</xref>
###xml 469 474 469 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Takahashi1">[103]</xref>
###xml 480 483 480 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 540 541 540 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 539 541 539 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 579 584 579 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Soker1">[100]</xref>
###xml 586 591 586 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Soker2">[104]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Fuh1">[14]</xref>
###xml 668 673 668 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Pan1">[105]</xref>
###xml 719 722 719 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 789 790 789 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 788 790 788 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 871 874 871 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 902 907 902 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Pan1">[105]</xref>
###xml 1003 1006 1003 1006 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1027 1030 1027 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1175 1180 1175 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ladomery1">[106]</xref>
###xml 1250 1253 1250 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1326 1327 1326 1327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 1325 1327 1325 1327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 1336 1339 1336 1339 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1364 1365 1364 1365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 1363 1365 1363 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 1388 1394 1388 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1475 1481 1475 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1602 1605 1602 1605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1609 1610 1609 1610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 1608 1610 1608 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 1661 1666 1661 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Filion1">[107]</xref>
###xml 1700 1703 1700 1703 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1707 1708 1707 1708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 1706 1708 1706 1708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 1788 1793 1776 1781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-AshikariHada1">[108]</xref>
###xml 1795 1800 1783 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Krilleke1">[109]</xref>
The control values for all binding and coupling kinetic rates (Table 3), except for the new interactions involving sVEGFR1, were kept identical to those from our previous single-compartment skeletal muscle model [54]. However, sensitivity analyses were performed to explore the following wide ranges cited in literature. VEGF affinity of VEGFR1 and VEGFR2 varied from Kd = 1-130 pM and 72-760 pM depending on culture cell type (e.g., HUVECs vs. tPAEs vs. HUCMECs) [94]-[103]. VEGF165 affinity of NRP1s additionally varied with assay type: Kd = 200-320 pM by cell-based Scatchard [100], [104] vs. 25-120 nM by cell-free BIAcore surface plasmon resonance analysis [14], [105]. In fact, against general consensus that VEGF121 does not bind NRP1, Pan et al. recently observed such binding at Kd = 220 nM (BIAcore), albeit at a lower affinity than the 120 nM reported for VEGF165 and NRP1 in the same study [105]. This finding coincided with recent observations that in addition to exon 7 of VEGF (which VEGF165 possesses while VEGF121 does not) that was traditionally associated with NRP-binding, exon 8 (which all VEGF isoforms have some form of) might also confer NRP-affinity [106]. We thus tested both scenarios: adding a new interaction between VEGF121 and NRP1 at a dissociation constant 1.83 times higher than our control Kd for VEGF165 and NRP1 (to match the Kd ratio measured by Pan et al.); and setting NRP1 affinities for both VEGF isoforms to the exact values as Pan et al. reported. Lastly, we explored lower VEGF-binding affinities for matrix sites, considering that our control value of VEGF165's Kd for matrix sites was estimated from that of FGF-2 [107], in light of indication that VEGF165's Kd for modified heparin could be approximately6-7 times higher than that of FGF-2 [108], [109].
###end p 73
###begin title 74
Kinetic Parameters of the VEGF system (Control Values).
###end title 74
###begin p 75
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ferrara1">[95]</xref>
For in vitro values: * assumed same as VEGF binding to VEGFR1 [95].
###end p 75
###begin p 76
###xml 20 23 20 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
assumed same as VEGF165 binding to GAG.
###end p 76
###begin p 77
###xml 14 17 14 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">off</sub>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 94 98 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Fuh1">[14]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
assumed same koff as VEGFR1 coupling to NRP1, with kon calculated to match Kd from literature [14] ; the rest were taken from [54].
###end p 77
###begin p 78
###xml 70 77 70 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
Conversions for in vivo values were based on geometry parameters from Table 1:
###end p 78
###begin p 79
###xml 134 142 134 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 251 253 251 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 292 296 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kendall1">[10]</xref>
###xml 298 302 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kendall2">[20]</xref>
###xml 314 322 302 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 406 410 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ferrara1">[95]</xref>
###xml 439 440 427 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 438 440 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 505 509 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 743 744 731 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 742 744 730 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 771 775 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 866 867 854 855 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 865 867 853 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 999 1000 987 988 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 998 1000 986 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 1011 1015 999 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Fuh1">[14]</xref>
###xml 1101 1102 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 1100 1102 1088 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 1144 1146 1132 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 1143 1146 1131 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>on</sub></italic>
###xml 1166 1169 1154 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">off</sub>
###xml 1165 1169 1153 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>off</sub></italic>
###xml 1217 1221 1205 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 235 240 <span type="species:ncbi:9606">human</span>
Regarding the new sVEGFR1 interactions with VEGF, matrix sites and NRP1, the following assumptions were made for their kinetic rates. In vitro experiments have characterized the VEGF-affinity of baculovirus-expressed and HUVEC-derived human sFlt-1 at Kdapproximately20 and 10 pM respectively [10], [20]. Given the in vitro evidence that the soluble and full-length VEGFR1's have similar affinities to VEGF [95], we assumed in our model a Kd of 33 pM for VEGF-sVEGFR1 binding, same as that previously used [54] for VEGF-VEGFR1 binding. To the best of our knowledge, sVEGFR1-binding affinities of various HSPGs have not been characterized. Despite the possible heparin-binding domain differences between VEGF and sVEGFR1, we took the effective Kd = 23.8 nM previously used [54] for VEGF binding to matrix-sites (ensemble of various HSPGs) as the control value of our Kd for sVEGFR1 binding to matrix-sites. BIAcore binding analysis of Flt-1 extracellular domains (ECDs) to immobilized NRP-1 showed a Kd of 1.8 nM [14]. Approximating sVEGFR1 as Flt-1 ECDs, we modeled sVEGFR1's affinity to NRP-1 with a Kd of 1.8 nM, subsequently calculating the kon based on the same koff as full-length VEGFR1's dissociation from NRP1 [54].
###end p 79
###begin title 80
3.3. Transport
###end title 80
###begin title 81
i. Macromolecular Vascular Permeability
###end title 81
###begin p 82
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 39 41 39 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Stefanini1">[59]</xref>
###xml 274 279 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 433 438 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Here, the vascular permeability rates (kP) characterized the microvasculatures' baseline (supine posture) capacity in allowing macromolecular transport across the endothelium, as in our previous study [59]. A new parameter representing endothelial surface area recruitment (gamma) was introduced to account for changes in the degree of perfusion within capillary beds as occurs during physiological redistribution of blood - e.g., a gamma<1 would represent effectively reduced transendothelial transport due to a larger fraction of unperfused or non-distended capillaries.
###end p 82
###begin p 83
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</sub>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</sub>
###xml 235 240 235 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.386</sup>
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Venturoli1">[86]</xref>
###xml 246 253 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t002">Table 2</xref>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</sub>
###xml 380 385 380 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Garlick1">[110]</xref>
###xml 442 443 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 460 465 460 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Schmittmann1">[111]</xref>
###xml 521 522 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</sub>
###xml 520 522 520 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>p</sub></italic>
###xml 546 553 546 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t004">Table 4</xref>
In determining the basal vascular permeability rates for the soluble species, their molecular weights (MW) were first converted into their Stokes-Einstein radii (aE) based on the empirical relation for globular proteins, aE = 0.483(MW)0.386[86] (Table 2). The corresponding permeability-surface area product (PS) were then determined from a set of theoretical curves for PS vs. aE[110]. Finally, assuming a capillary surface area (S) of 70 cm2/g muscle tissue [111], the molecular species-specific basal permeabilities (kp = PS/S) were obtained (Table 4).
###end p 83
###begin title 84
Transport Parameters: Basal Vascular Permeability and Plasma Clearance Rates.
###end title 84
###begin p 85
###xml 44 52 44 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1b</xref>
Calibrated based on hydrodynamic sizes from Table 1b.
###end p 85
###begin p 86
###xml 69 76 69 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t005">Table 5</xref>
###xml 891 896 883 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Cisek1">[112]</xref>
###xml 1259 1264 1243 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Dawson1">[113]</xref>
###xml 1266 1271 1250 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Clark1">[114]</xref>
###xml 456 460 <span type="species:ncbi:9913">calf</span>
###xml 927 931 <span type="species:ncbi:9913">calf</span>
###xml 1230 1234 <span type="species:ncbi:10116">rats</span>
###xml 1239 1245 <span type="species:ncbi:9606">humans</span>
###xml 1317 1321 <span type="species:ncbi:9913">calf</span>
The posture and activity-dependent surface area recruitment factors (Table 5) were approximated as follows. The effective vascular permeabilities of the normal "rest of the body" compartment were maintained at basal levels (gamma = 1) in both supine (lying down) and dependent (sitting/standing) positions, assuming there to be little change after averaging the pressure/perfusion changes to tissue masses above and below the heart level. For the "healthy calf" compartment, however, the venoarterial reflex - which normally decreases foot perfusion in response to moving from a supine to dependent position in compensation to the gravitational hydrostatic hypertension - was taken into consideration. Specifically, foot skin blood perfusion in normal subjects has been found to decrease from 7.8+/-2.2 mL/min/100 g in the supine position to 2.8+/-0.6 mL/min/100 g in the dependent position [112]. We thus assumed the "healthy calf" compartment to take on the basal permeabilities when at rest (gamma = 1 for supine) and at 3/8 of the basal levels when standing (gamma = 0.375 for dependent). Exercise, on the other hand, has been shown to increase capillary surface area available for perfusion up to 2x and 3x resting levels in rats and humans respectively [113], [114]; we thus allowed gamma = 3 for an exercising calf.
###end p 86
###begin title 87
Transport Parameters: Surface Area Recruitment Factor for Effective Vascular Permeability Rates.
###end title 87
###begin p 88
VAR = venoarterial reflex.
###end p 88
###begin title 89
ii. Lymphatic Drainage
###end title 89
###begin p 90
###xml 166 171 166 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kivela1">[115]</xref>
###xml 290 297 290 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g001">Fig. 1A</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aukland1">[62]</xref>
###xml 953 960 953 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t006">Table 6</xref>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
In mice quadriceps femoris skeletal muscle, capillary-sized lymphatic vessels were found next to blood capillaries between muscle fibers, but at a much lower density [115]. Hence the small volume of the lymphatic capillary space was not explicitly partitioned within our tissue geometries (Fig. 1A). There is no macromolecular size-dependence in the filling of the initial lymphatics (unlike macromolecular permeability through blood capillaries) [62], thus protein concentrations drained through the lymphatics were modeled as continuous with those in the available interstitial fluid. Moreover, fluid transfer through the lymphatics was assumed to have negligible effects on volume and protein concentration changes in interstitial fluid and plasma. This was consistent with our representation of vascular permeability where only macromolecular but not hydraulic transport was represented in the model. The following parameterization is summarized in Table 6.
###end p 90
###begin title 91
Transport Parameters - Lymphatic Flow Rates.
###end title 91
###begin p 92
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 176 180 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Alitalo1">[60]</xref>
###xml 182 187 158 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Moore1">[116]</xref>
###xml 189 194 165 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Xu1">[117]</xref>
###xml 60 63 <span type="species:ncbi:9606">man</span>
Conversions are based on: a the mass composition of a 70-kg man as 5-kg blood, approximately14 kg non-lymphatically drained mass, approximately51 kg lymphatically drained mass [60], [116], [117].
###end p 92
###begin p 93
###xml 25 32 25 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 48 52 48 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Elliott1">[72]</xref>
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ward1">[87]</xref>
###xml 8 12 <span type="species:ncbi:9913">calf</span>
healthy calf volume from Table 1 with 1.06 g/cm3[72], [87].
###end p 93
###begin p 94
assuming all tissues to have the skeletal muscle lymph flow rate.
###end p 94
###begin p 95
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Alitalo1">[60]</xref>
###xml 210 215 210 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Moore1">[116]</xref>
###xml 236 241 224 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Xu1">[117]</xref>
###xml 449 453 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Elliott1">[72]</xref>
###xml 455 459 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ward1">[87]</xref>
###xml 669 671 605 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 674 675 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 687 691 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aukland1">[62]</xref>
###xml 781 782 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 915 916 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1078 1083 1014 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Olszewski1">[118]</xref>
###xml 1431 1436 1367 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Olszewski1">[118]</xref>
###xml 1438 1443 1374 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Olszewski2">[119]</xref>
###xml 1538 1542 1474 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Havas2">[64]</xref>
###xml 443 447 <span type="species:ncbi:9913">calf</span>
###xml 577 582 <span type="species:ncbi:9606">human</span>
###xml 733 737 <span type="species:ncbi:9913">calf</span>
To approximate the total mass of body tissue subjected to lymphatic drainage, the masses of organs with no lymphatic capillaries (entire central nervous system, lens, cornea, bone, bone marrow, epidermis [60], [116]; approximately14 kg [117]) and the mass of blood (approximately5 kg) were first subtracted from 70-kg total body mass. The resulting 51 kg of body tissue drained by lymphatics was then divided between the approximately0.92 kg "calf" [72], [87] and the approximately50.08 kg "normal" compartments. The night-time (asleep; supine position) lymph flow per gram of human skeletal muscle was measured to be approximately2 microL/h/g skeletal muscle or 5.6x10-7 cm3/s/g tissue [62]. Thus the night-time lymph flow for the "calf" compartment was determined to be 0.0005 cm3/s. Approximating all other lymphatically-drained organs to have the skeletal muscle lymph flow rate yielded a lymph flow of 0.028 cm3/s for the "normal" compartment. Awakeness alone (awake; supine posture) was found to increase the average basal lymph flow rates to about 5-fold of night values [118]; these day-time basal values were taken as the control rates for our simulations. Additionally, healthy subjects would experience a range of muscle activity-dependent lymph flow rates through the course of a day. Lymph flow was found to increase 10 to 13-fold from basal night levels during normal daily activities (steady-state standing/walking) [118], [119], and could peak to 5-fold of basal day levels at 1 h post-onset of exercise (running/cycling) [64].
###end p 95
###begin title 96
iii. Plasma Clearance
###end title 96
###begin p 97
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 74 77 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#964;</italic>
###xml 88 90 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 87 90 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
###xml 139 146 137 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t004">Table 4</xref>
###xml 567 568 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 566 568 564 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 620 621 618 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 619 621 617 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>c</sub></italic>
###xml 624 626 622 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 623 626 621 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>on</sub></italic>
###xml 650 653 648 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sub>
###xml 649 653 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>int</sub></italic>
###xml 708 714 706 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 856 861 854 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Eppler1">[120]</xref>
###xml 916 919 914 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 930 932 928 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 943 945 941 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 947 949 945 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1250 1252 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1254 1256 1228 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1256 1261 1230 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Holash1">[121]</xref>
###xml 1263 1268 1237 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Nguyen1">[122]</xref>
###xml 1387 1389 1361 1363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1391 1393 1365 1367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
The plasma clearance rates (kCL, in units of s-1) or terminal half-lives (tau = (ln 2)/kCL, in units of s) of proteins used in this model (Table 4) represented the non-specific physiological elimination processes that include kidney filtration, liver conjugation, and proteolytic catabolism. Where possible, we distinguished this type of clearance from the early plasma clearance processes such as rapid uptake by various tissue organs (biodistribution phase), which was represented separately in our model by the extravasation of proteins into tissue compartments (kP) with subsequent receptor-specific sequestration (kc, kon) and internalization (kint). For VEGF in particular, we approximated from Eppler et al.'s compartmental model that distinguished between receptor-specific tissue uptake and non-specific elimination components of plasma clearance [120]. Their fitted dose-independent clearance rate for VEGF165 was 3.89 h-1 or 1.08x10-3 s-1, corresponding to an effective clearance half-life of approximately10.7 min. Synthetic soluble VEGF-traps that consisted of partial extracellular domains of VEGFR1 (or VEGFR1 and VEGFR2) fused to the Fc region of IgG1 (dimers) were found to have clearance rates in the range of approximately3 to 8x10-6 s-1[121], [122]. Thus for endogenous sVEGFR1 and VEGF-sVEGFR1, with no documented clearance rates, we assumed a clearance rate of 5x10-6 s-1.
###end p 97
###begin title 98
3.4. Protein Expression Levels
###end title 98
###begin title 99
i. Interstitial Matrix Binding Sites for VEGF and sVEGFR1
###end title 99
###begin p 100
###xml 80 83 80 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 217 222 217 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Robinson1">[123]</xref>
###xml 269 274 269 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Robinson1">[123]</xref>
###xml 388 395 388 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t007">Table 7</xref>
###xml 599 604 599 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Mitsi1">[124]</xref>
###xml 625 630 625 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kreuger1">[125]</xref>
###xml 705 710 705 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Xiao1">[126]</xref>
###xml 712 717 712 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Mosher1">[127]</xref>
Of the various types of glycosaminoglycans (GAGs) present on proteoglycans, VEGF165 interacts predominantly with heparin and heparan sulfates (HS), while considerably less with chondroitin sulfate or dermatan sulfate [123]. As heparin is mostly localized on mast cells [123], we derived our matrix-specific VEGF-binding site densities from only HS-proteoglycans (HSPGs), as summarized in Table 7. Other contributions to VEGF-binding matrix sites from glycoproteins such as fibronectin were ignored due to having concentrations 1-3 orders of magnitude lower than HSPG contributions in the ECM and BM [124]. Cell-surface HSPGs [125], as well as soluble-HSs, soluble-fibronectins and platelets in the plasma [126], [127], were also not explicitly modeled.
###end p 100
###begin title 101
Total Interstitial VEGF/sVEGFR1-Binding Site Densities, Based on Matrix Heparan Sulfate Proteoglycans (HSPGs).
###end title 101
###begin p 102
EHS = Engelbreth-Holm-Swarm.
###end p 102
###begin p 103
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Levick1">[83]</xref>
SkM = skeletal muscle. Conversions are based on: a cell volume fraction of 0.57 in tumor tissue [83].
###end p 103
###begin p 104
average 387-kDa HSPG [see text].
###end p 104
###begin p 105
###xml 40 45 40 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Rohrbach1">[128]</xref>
the IS of EHS tumors is homogenously BM [128].
###end p 105
###begin p 106
approximately4.2 VEGF-binding sites per HSPG.
###end p 106
###begin p 107
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BM</sub>
###xml 75 77 75 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BM</sub>
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
31% (available fluid/fluid volume)BM and 18% (available fluid/total volume)BM based on Table 1 geometry.
###end p 107
###begin p 108
###xml 115 119 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 121 126 121 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Filion1">[107]</xref>
###xml 291 296 291 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Rohrbach1">[128]</xref>
###xml 428 436 428 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 513 518 513 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Rohrbach1">[128]</xref>
###xml 520 525 520 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kleinman1">[129]</xref>
###xml 710 715 710 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Iozzo1">[130]</xref>
###xml 731 736 731 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Jenniskens1">[131]</xref>
###xml 764 769 764 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Jenniskens1">[131]</xref>
###xml 817 822 805 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hileman1">[132]</xref>
###xml 1026 1031 1002 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Iozzo1">[130]</xref>
###xml 1033 1038 1009 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Jenniskens1">[131]</xref>
###xml 1088 1091 1052 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1101 1106 1065 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Robinson1">[123]</xref>
###xml 1181 1186 1143 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Robinson1">[123]</xref>
###xml 1188 1193 1150 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kreuger1">[125]</xref>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
In the ECM, the VEGF-binding matrix-site densities were estimated from FGF-binding sites as in our previous models [54], [107]. In the BMs, we modeled the HSPG content of both tissue compartments based on measurements from Engelbreth-Holm-Swarm (EHS) sarcomas in control (non-diabetic) mice [128]. EHS mouse tumors produce a homogenous interstitial matrix of basement membrane material, making EHS interstitial matrix a typical in vitro model for physiological BMs which are usually too thin for content analysis [128], [129]. To convert the HSPG protein weights into molar concentrations, we assumed the average HSPG to weigh 387 kDa - a sum of the 300 kDa protein core weight (averaged over 470-kDa Perlecan [130], 250-kDa Agrin [131], 180-kDa Collagen XVIII PG [131]) and approximately3 HS-chains (averaged 29 kDa [132]) per HSPG. To convert the HSPG content into VEGF-binding site densities, we further assumed an average of 4.2 VEGF-binding sites per HSPG, based on experiments showing: approximately3 HS-chains per HSPG [130], [131]; approximately30% of HS-chains displaying no VEGF165 affinity [123]; >/=2 VEGF-binding sequences ("SAS domains") present within each HS-chain [123], [125].
###end p 108
###begin p 109
Due to insufficient literature data on the availability of sVEGFR1-binding sites on HSPGs, we did not separately calculate their corresponding densities and instead assumed that sVEGFR1 would share (competitively) the same matrix sites with VEGF.
###end p 109
###begin title 110
ii. Endothelial Cell Surface Receptors
###end title 110
###begin p 111
###xml 116 121 116 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ryan1">[133]</xref>
###xml 123 128 123 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Croley1">[134]</xref>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 438 445 438 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 834 838 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hazarika1">[19]</xref>
###xml 840 844 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Bikfalvi1">[96]</xref>
###xml 845 849 845 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Waltenberger1">[98]</xref>
###xml 989 996 989 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t008">Table 8</xref>
###xml 35 39 <span type="species:ncbi:9913">calf</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
For the "normal body" and "healthy calf" compartments, we converted the same VEGFR1 and VEGFR2 protein measurements [133], [134] from human vastus lateralis muscles referenced in our previous models [54] - using our new geometric properties (73 cm2/cm3 tissue) and dimeric molecular weights of the VEGFRs - to get corresponding density ranges of 60,000-68,000 VEGFR1 and 10,000-14,000 VEGFR2 per endothelial cell. NRP1 protein expression in vivo has yet to be documented in literature. As before [54], we interpreted these density ranges as upper bounds for our control values - assumed at 10,000/EC for all VEGFRs - since the measurements did not discriminate between intracellular vs. surface-bound vs. soluble forms of the receptors. There was also evidence suggesting VEGFR2 densities may actually be higher than VEGFR1 densities [19], [96]-[98]. Without definitive quantification, we assumed a 1:1:1 ratio of VEGFR1:VEGFR2:NRP1 densities at control. Converted values are tabulated in Table 8.
###end p 111
###begin title 112
Total Surface Receptor Densities.
###end title 112
###begin p 113
###xml 111 116 111 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Green1">[167]</xref>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ward1">[87]</xref>
###xml 169 174 169 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Takahashi1">[103]</xref>
###xml 202 207 202 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Takahashi1">[103]</xref>
###xml 259 266 259 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
###xml 31 36 <span type="species:ncbi:9606">human</span>
Experimental measurements from human vastus lateralis muscle. Conversions are based on 155 mg protein/g tissue [167], 1.06 g/cm3 tissue [87] , 360-kDa VEGFR1 homodimers [103], 460-kDa VEGFR2 homodimers [103] and microvessel surface area densities (ESAV) from Table 1.
###end p 113
###begin title 114
iii. Interstitial Free VEGF and sVEGFR1
###end title 114
###begin p 115
###xml 146 151 146 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gavin1">[135]</xref>
###xml 153 158 153 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hoffner1">[136]</xref>
###xml 311 318 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t009">Table 9</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hazarika1">[19]</xref>
###xml 678 685 678 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t009">Table 9</xref>
###xml 11 17 <span type="species:ncbi:9606">humans</span>
###xml 292 296 <span type="species:ncbi:9913">calf</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
In healthy humans at rest, the interstitial free VEGF concentration has been measured in vastus lateralis microdialysates to be about 12-50 pg/mL [135], [136], which converts to 0.26-1.1 pM based on 46-kDa VEGF dimers. We thus targeted a range of 0.5-1.0 pM in the "normal body" and "healthy calf" interstitia (Table 9). The basal interstitial sVEGFR1 concentrations have not been reported in the literature. We thus estimated a target range for interstitial sVEGFR1 concentrations - by scaling the target range for interstitial VEGF concentrations to the VEGF:sVEGFR1 protein weight measurements in tibialis anterior (TA) homogenates in normal mice [19] - at about 0.6-1.2 pM (Table 9). Limitations were noted in extrapolating from homogenate measurements that did not discriminate between interstitial and intracellular proteins. Thus in the case that plasma and interstitial concentrations could not be simultaneously modeled, we opted to fit targeted ranges for plasma concentrations in violation of the interstitial targets.
###end p 115
###begin title 116
Steady-State Interstitial Concentrations of VEGF and sVEGFR1.
###end title 116
###begin p 117
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 47 52 47 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Takahashi1">[103]</xref>
Conversions are based on: a 46-kDa VEGF-dimers [103].
###end p 117
###begin p 118
220-kDa sVEGFR1-homodimers.
###end p 118
###begin title 119
iv. Plasma Free VEGF and sVEGFR1
###end title 119
###begin p 120
###xml 138 142 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Blann1">[44]</xref>
###xml 143 147 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Makin1">[46]</xref>
###xml 191 195 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Bailey1">[49]</xref>
###xml 197 202 173 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kraus1">[137]</xref>
###xml 204 209 180 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gavin2">[138]</xref>
###xml 271 279 247 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t010">Table 10</xref>
In healthy subjects, measurements of plasma VEGF concentrations generally fell within two ranges: 78-113 pg/mL plasma (approximately2 pM) [44]-[46] and 32-41 pg/mL plasma (approximately1 pM) [49], [137], [138]. We thus simulated plasma VEGF at 1.5 pM as healthy control (Table 10).
###end p 120
###begin title 121
Steady-State Plasma Concentrations of VEGF and sVEGFR1.
###end title 121
###begin p 122
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 47 52 47 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Takahashi1">[103]</xref>
Conversions are based on: a 46-kDa VEGF-dimers [103].
###end p 122
###begin p 123
220-kDa sVEGFR1-homodimers.
###end p 123
###begin p 124
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aref1">[39]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Shapiro1">[40]</xref>
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Diab1">[42]</xref>
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Chung1">[52]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Blann1">[44]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Chung1">[52]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Blann1">[44]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Belgore1">[45]</xref>
###xml 644 652 632 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t010">Table 10</xref>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
Literature data on plasma sVEGFR1 concentrations were significantly more heterogeneous [39], [40], [42]-[52]. In defining our target ranges, we limited our sources to healthy control data from PAD-specific studies, for consistency in data source compared to our concurrent studies modeling PAD patients. Since most healthy measurements from studies on other atherosclerotic vascular diseases (e.g. coronary artery disease (CAD), diabetes with atherosclerosis [44], [52]) also supported the higher healthy control range of 21-22 ng/mL as reported in PAD studies [44], [45], we simulated plasma sVEGFR1 at approximately100 pM as healthy control (Table 10), such that our "healthy subject" was defined within the same control demographics typically considered in PAD/CAD/diabetic studies.
###end p 124
###begin title 125
4. Numerical Solutions & Computational Simulations
###end title 125
###begin p 126
###xml 485 487 485 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 537 539 537 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
All simulations and data plots presented in this chapter were performed on the numerical computing platform, MATLAB 7.3.0 R2006b (MathWorks, Natick, MA), and run on a desktop PC. The full system of coupled nonlinear ODEs described above was solved as an initial value problem to steady state using MATLAB's 'ode15s' solver routine (a multi-step variable-order stiff problem solver that employs the numerical differentiation formulas scheme), with the relative error tolerance set at 10-6 (0.0001% accuracy) and an initial step size of 10-4.
###end p 126
###begin p 127
###xml 342 350 342 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t009">Tables 9</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t010">10</xref>
###xml 496 504 496 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t003">Tables 3</xref>
###xml 508 508 508 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t004"/>
###xml 508 508 508 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t005"/>
###xml 508 508 508 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t006"/>
###xml 508 508 508 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t007"/>
###xml 508 509 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t008">8</xref>
The following is an outline of the simulation experiments performed and the organizational structure of the results section below. Results section 1 covers the initial steps of finding the tissue secretion rates necessary to reproduce a healthy control subject's expected ranges of interstitial and plasma concentrations of VEGF and sVEGFR1 (Tables 9 and 10), with all other parameters (geometry, kinetics, transport and protein expression) set at values summarized for a supine healthy subject (Tables 3 to 8). At the established control settings, a detailed molecular characterization of the healthy model is then given: the steady-state compartmental distributions of total VEGF and sVEGFR1; the tissue-specific profiles of matrix site occupancies and receptor signaling; and the balance of mass flows. Such characterization proved useful in explaining VEGF/sVEGFR1 system responses observed in subsequent parameter sensitivity analyses of: the secretion rates of VEGF and sVEGFR1 (Results section 2); surface receptor densities (section 3); VEGF-affinities of surface receptors (section 4); VEGF-affinities of interstitial matrix sites (section 5); and transport parameters (section 6).
###end p 127
###begin title 128
Results
###end title 128
###begin title 129
###xml 44 49 <span type="species:ncbi:9606">human</span>
1. Determining basal profiles for a healthy human subject
###end title 129
###begin title 130
###xml 131 135 <span type="species:ncbi:9913">calf</span>
1.1. Targeting experimental plasma concentrations of VEGF and sVEGFR1 as functions of their secretion rates from the "normal" and "calf" compartments
###end title 130
###begin p 131
In our stepwise search for the set of secretion rates that could computationally replicate the interstitial and plasma concentrations of VEGF and sVEGFR1 expected from experimental data in our healthy control model, we first established the VEGF concentrations in absence of sVEGFR1, and then introduced sVEGFR1 at modified secretion rates.
###end p 131
###begin p 132
###xml 40 43 40 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 120 122 120 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 127 129 127 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 237 253 237 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 259 273 259 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 310 313 310 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 322 325 322 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 360 368 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A:</xref>
###xml 396 398 396 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 396 398 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 448 450 448 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 448 450 448 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 554 556 542 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 554 556 542 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 692 694 680 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 692 694 680 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 730 732 718 720 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 730 732 718 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 805 812 793 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,-Ctrl</sub>
###xml 817 833 805 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 836 850 824 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 217 221 <span type="species:ncbi:9913">calf</span>
###xml 269 273 <span type="species:ncbi:9913">Calf</span>
###xml 755 759 <span type="species:ncbi:9913">calf</span>
###xml 846 850 <span type="species:ncbi:9913">Calf</span>
In the absence of sVEGFR1 expressions (qsR1 = 0), the steady-state plasma and interstitial free VEGF concentrations ([V]pl, [V]IS) were mapped out as functions of total VEGF-secretion rates from the normal tissue and calf compartments (qTotalVEGF,Normal and qTotalVEGF,Calf), where the individual isoforms VEGF121 and VEGF165 were secreted at a ratio of 1:10 (Fig. 2A: top row, '-sR1'). Where [V]pl was within the experimental ranges of 1-2 pM, [V]IS were predicted to be approximately10-fold higher, in contradiction of microdialysis measurements of [V]IS at around 1 pM. Therefore, in the absence of sVEGFR1 expression, the control VEGF-secretion rates necessary to achieve the targeted [V]pl of 1.5 pM, as well as symmetric [V]IS (i.e., 15 pM in both "calf" and "normal" interstitia), would have been qV,-Ctrl = (qTotalVEGF,Normal, qTotalVEGF,Calf) = (0.264, 0.154) molecules/MD/s.
###end p 132
###begin title 133
###xml 41 50 41 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF</sub>
Targeting Control VEGF-Secretion Rates (qTotalVEGF) for Basal Profile of Healthy Subject.
###end title 133
###begin p 134
###xml 139 148 139 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF</sub>
###xml 3 193 3 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Steady-state sensitivity of plasma and interstitial concentrations of free VEGF (top and middle rows) and free sVEGFR1 (bottom row) to q<sub>TotalVEGF</sub> from normal tissue (y-axis) and calf (x-axis</italic>
###xml 241 244 241 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 249 252 249 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 261 276 261 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Top/middle row:</italic>
###xml 301 304 301 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 413 420 413 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,-Ctrl</sub>
###xml 425 441 425 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 444 458 444 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 533 536 533 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 540 548 540 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Ctrl</sub>
###xml 780 787 780 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,+Ctrl</sub>
###xml 792 808 792 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 811 825 811 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 940 947 940 947 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,-Ctrl</sub>
###xml 953 960 953 960 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,+Ctrl</sub>
###xml 975 986 975 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bottom row:</italic>
###xml 1148 1162 1148 1162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 1381 1390 1381 1390 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF</sub>
###xml 1277 1391 1277 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Density of VEGF-VEGFR complexes changed in proportion to interstitial free VEGF levels with increasing q<sub>TotalVEGF</sub>.</italic>
###xml 1632 1635 1632 1635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1650 1653 1650 1653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 181 185 <span type="species:ncbi:9913">calf</span>
###xml 454 458 <span type="species:ncbi:9913">Calf</span>
###xml 821 825 <span type="species:ncbi:9913">Calf</span>
###xml 1099 1103 <span type="species:ncbi:9913">calf</span>
###xml 1158 1162 <span type="species:ncbi:9913">Calf</span>
###xml 1509 1513 <span type="species:ncbi:9913">calf</span>
A. Steady-state sensitivity of plasma and interstitial concentrations of free VEGF (top and middle rows) and free sVEGFR1 (bottom row) to qTotalVEGF from normal tissue (y-axis) and calf (x-axis. VEGF isoforms were secreted at a ratio of VEGF121:VEGF165 = 1:10. Top/middle row: In absence of sVEGFR1 (qsR1 = 0; labelled '-sR1'), plasma free VEGF reached the targeted 1.5 pM at the control VEGF-secretion rates of qV,-Ctrl = (qTotalVEGF,Normal, qTotalVEGF,Calf) = (0.264,0.154) molecule/MD/s. The incorporation of sVEGFR1 expression (qsR1 = qsR1,Ctrl; labelled '+sR1') raised plasma VEGF significantly (red arrow) but with negligible effects on interstitial VEGF. To keep plasma free VEGF at the targeted 1.5 pM, the control VEGF-secretion rates were redefined (green arrow) to be qV,+Ctrl = (qTotalVEGF,Normal, qTotalVEGF,Calf) = (0.1925,0.1155) molecule/MD/s. Grey and beige spheres mark the interstitial and plasma VEGF levels reached at qV,-Ctrl and qV,+Ctrl respectively. Bottom row: Despite sVEGFR1's role as a VEGF sink, free sVEGFR1 only changed inversely relative to free VEGF changes in the calf interstitum in the direction of increasing qTotalVEGF,Calf. Orange/black arrows indicate inverse/direct relation between sVEGFR1 concentrations and VEGF-secretion rates. B. Density of VEGF-VEGFR complexes changed in proportion to interstitial free VEGF levels with increasing qTotalVEGF. Bracketed percentages are VEGF-bound fractional occupancies of total VEGFR, averaged (range<0.3%) between normal and calf compartments. In figure: '+' = control; 'max' and 'min' bound targeted ranges; 'MD' = myonuclear domain; 'V121' = VEGF121; 'V165' = VEGF165; 'R1' = VEGFR1; 'sR1' = sVEGFR1; 'R2' = VEGFR2.
###end p 134
###begin p 135
###xml 66 74 66 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A:</xref>
###xml 188 195 188 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,-Ctrl</sub>
###xml 200 202 200 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 200 202 200 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 287 289 287 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 287 289 287 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 405 412 405 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,+Ctrl</sub>
###xml 417 433 417 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 436 450 436 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 500 503 500 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;18</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 536 538 536 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 536 538 536 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 703 705 703 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 703 705 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 712 714 712 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 712 714 712 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 821 831 821 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Normal</sub>
###xml 837 845 837 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Calf</sub>
###xml 850 857 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig. 3A</xref>
###xml 894 901 894 901 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,+Ctrl</sub>
###xml 964 966 964 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 964 966 964 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1004 1006 1004 1006 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 1084 1092 1084 1092 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Ctrl</sub>
###xml 1097 1108 1097 1108 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1, Normal</sub>
###xml 1111 1119 1111 1119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Calf</sub>
###xml 1169 1172 1169 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;19</sup>
###xml 1182 1183 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1204 1212 1204 1212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Ctrl</sub>
###xml 1217 1219 1217 1219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 1217 1219 1217 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1264 1266 1264 1266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 1264 1266 1264 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 1281 1289 1281 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A:</xref>
###xml 1375 1377 1375 1377 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 1375 1377 1375 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1387 1389 1387 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 1387 1389 1387 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1487 1489 1487 1489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 1487 1489 1487 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1590 1597 1590 1597 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V,+Ctrl</sub>
###xml 1603 1611 1603 1611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Ctrl</sub>
###xml 1613 1621 1613 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t011">Table 11</xref>
###xml 1636 1638 1636 1638 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 1636 1638 1636 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 446 450 <span type="species:ncbi:9913">Calf</span>
###xml 801 805 <span type="species:ncbi:9913">calf</span>
###xml 841 845 <span type="species:ncbi:9913">Calf</span>
###xml 1028 1032 <span type="species:ncbi:9913">calf</span>
###xml 1115 1119 <span type="species:ncbi:9913">Calf</span>
However, the incorporation of sVEGFR1 expression into the system (Fig. 2A: '+sR1') was found to shift the VEGF profile upwards in the plasma - i.e., if VEGF-secretion rates were fixed at qV,-Ctrl, [V]pl became 2.1 pM once sVEGFR1-secretion rates were high enough to attain a target [sR1]pl of 100 pM. Hence in seeking our control sVEGFR1-secretion rates, we redefined the control VEGF-secretion rates to qV,+Ctrl = (qTotalVEGF,Normal, qTotalVEGF,Calf) = (0.1925, 0.1155) molecule/MD/s = (9.3, 5.7).10-18 mole/(cm3 tissue)/s, so that [V]pl would start off at the lower bound of the target range (1 pM) in the absence of sVEGFR1. The steady-state plasma and interstitial free sVEGFR1 concentrations ([sR1]pl, [sR1]IS) were then plotted over a range of sVEGFR1-secretion rates from the normal tissue and calf compartments (qsR1,Normal and qsR1,Calf) in Fig. 3A, while VEGF-secretion was fixed at qV,+Ctrl. The control sVEGFR1-secretion rates that could attain a [sR1]pl of 100 pM, as well as symmetric [sR1]IS (i.e, 36 pM in both "calf" and "normal" interstitia), were determined to be qsR1,Ctrl = (qsR1, Normal, qsR1,Calf) = (0.0107,0.0210) molecules/EC/s = (1.3, 1.5).10-19 moles/(cm3 tissue)/s. At this qsR1,Ctrl, [V]pl became exactly the targeted 1.5 pM, with [V]IS now at 10 pM (Fig. 2A: middle row). Although the control secretion rates needed to reach a target set of [V]pl and [sR1]pl were not unique - i.e., higher sVEGFR1-secretion rates could theoretically also have elevated [V]pl from below 1 pM in absence of sVEGFR1 to 1.5 pM in presence of sVEGFR1 - we settled on this set of qV,+Ctrl and qsR1,Ctrl (Table 11) such that [V]pl remained within experimental range, with or without sVEGFR1 expression in the simulation.
###end p 135
###begin title 136
###xml 44 47 44 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
Targeting Control sVEGFR1-Secretion Rates (qsR1) for Basal Profile of Healthy Subject.
###end title 136
###begin p 137
###xml 127 130 127 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 3 176 3 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Steady-state sensitivity of plasma and interstitial concentrations of free VEGF (top row) and free sVEGFR1 (bottom row) to q<sub>sR1</sub> from normal tissue (y-axis) and calf (x-axis)</italic>
###xml 178 186 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Top row:</italic>
###xml 270 273 270 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 383 394 383 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bottom Row:</italic>
###xml 488 496 488 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Ctrl</sub>
###xml 501 511 501 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Normal</sub>
###xml 514 522 514 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Calf</sub>
###xml 631 639 631 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Ctrl</sub>
###xml 697 700 697 700 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 644 700 644 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Density of VEGF-VEGFR complexes were insensitive to q<sub>sR1</sub></italic>
###xml 952 955 952 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 970 973 970 973 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 163 167 <span type="species:ncbi:9913">calf</span>
###xml 518 522 <span type="species:ncbi:9913">Calf</span>
###xml 819 823 <span type="species:ncbi:9913">calf</span>
A: Steady-state sensitivity of plasma and interstitial concentrations of free VEGF (top row) and free sVEGFR1 (bottom row) to qsR1 from normal tissue (y-axis) and calf (x-axis). Top row: Interstitial free VEGF decreased while plasma free VEGF increased with increasing qsR1. Blue/black arrows indicate inverse/direct relation between VEGF concentrations and sVEGFR1-secretion rates. Bottom Row: The targeted 100 pM of free sVEGFR1 was reached in plasma at the control secretion rates of qsR1,Ctrl = (qsR1,Normal, qsR1,Calf) = (0.0107,0.0210) molecule/EC/s. Beige spheres mark the interstitial and plasma sVEGFR1 levels reached at qsR1,Ctrl. B: Density of VEGF-VEGFR complexes were insensitive to qsR1. Bracketed percentages are VEGF-bound fractional occupancies of total VEGFR, averaged (range<0.4%) between normal and calf compartments. In figure: '+' = control; 'max', 'min' and 'mean' indicate targeted ranges; 'EC' = endothelial cell; 'V121' = VEGF121; 'V165' = VEGF165; 'R1' = VEGFR1; 'sR1' = sVEGFR1; 'R2' = VEGFR2.
###end p 137
###begin title 138
VEGF- and sVEGFR1-Secretion Rates (Fitted Kinetic Parameters).
###end title 138
###begin p 139
MD = myonuclear domain (parenchymal cell unit).
###end p 139
###begin p 140
EC = endothelial cells.
###end p 140
###begin p 141
IS = interstitial space.
###end p 141
###begin p 142
###xml 50 57 50 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
Conversions are based on geometry parameters from Table 1:
###end p 142
###begin title 143
1.2. Basal distribution profiles
###end title 143
###begin p 144
###xml 178 185 178 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1</xref>
Using the aforementioned control secretion rates, the following molecular distributions and occupancy profiles were achieved at steady state. (See "Healthy Ctrl" in Supplemental Fig. S1 for details.)
###end p 144
###begin title 145
i. VEGF distribution
###end title 145
###begin p 146
###xml 22 25 22 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 30 33 30 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 113 122 113 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-A</xref>
###xml 235 238 235 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 247 250 247 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 291 302 291 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-C,D</xref>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 532 536 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Belgore1">[45]</xref>
###xml 570 573 558 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 578 581 566 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 691 702 679 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-C,D</xref>
###xml 735 738 723 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 743 746 731 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 856 867 844 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-C,D</xref>
###xml 1121 1125 1109 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 1127 1131 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Stefanini1">[59]</xref>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 712 716 <span type="species:ncbi:9913">calf</span>
The ratio of free VEGF121:VEGF165 in plasma and interstitial concentrations were 1:10.8 and 1:10.6 respectively (Fig. S1-A), just slightly lower than the original isoform ratio of the VEGF-secretion rate (1:10). In the blood, both VEGF121 and VEGF165 were 23% free and 77% bound to sVEGFR1 (Fig. S1-C,D). This predicted complexed fraction of VEGF was much higher than that experimentally measured by Belgore et al. in healthy human plasma (approximately4% mole fraction, based on 113 pg/mL free VEGF and 18 pg/mL complexed sVEGFR1) [45]. In the normal interstitium, VEGF121:VEGF165 were 0.9%:0.6% free, 0.8%:0.6% sVEGFR1-bound, 98.3%:63.0% surface receptor-bound, and 0%:35.8% matrix-bound (Fig. S1-C,D). In the calf interstitium, VEGF121:VEGF165 were 4.8%:1.4% free, 5.0%:1.5% sVEGFR1-bound, 90.2%:24.7% surface receptor-bound, and 0%:72.4% matrix-bound (Fig. S1-C,D). In other words, while VEGF was mostly bound to sVEGFR1 in blood, almost all extracellular VEGF in muscle tissue was surface receptor- or matrix-bound. Compared to our previous single-compartment and multi-compartment results in the absence of sVEGFR1 [54], [59], the addition of sVEGFR1 into the VEGF system did not significantly alter the predicted total VEGF distribution in normal muscle tissue.
###end p 146
###begin title 147
ii. sVEGFR1 distribution
###end title 147
###begin p 148
###xml 78 87 78 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-B</xref>
###xml 317 321 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Belgore1">[45]</xref>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 337 341 <span type="species:ncbi:9913">calf</span>
In the blood, 95% of total sVEGFR1 were free, with only 5% complexed to VEGF (Fig. S1-B). This predicted VEGF-occupancy of total plasma sVEGFR1 was again higher than that experimentally measured in healthy human plasma (approximately0.65% mole fraction, based on 21 ng/mL free sVEGFR1 vs. 18 pg/mL complexed sVEGFR1) [45]. In the normal:calf interstitium, sVEGFR1 were 1.6%:1.9% free, 97.4% matrix-bound, 0.4%:0.6% VEGF-bound (with or without NRP1 coupling), and 0.6%:0.1% NRP1-bound.
###end p 148
###begin title 149
iii. Inter-compartmental distributions
###end title 149
###begin p 150
###xml 223 230 223 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
###xml 400 407 400 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t001">Table 1</xref>
###xml 515 518 515 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 597 600 597 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 681 694 681 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-B,C,D</xref>
###xml 245 249 <span type="species:ncbi:9913">calf</span>
###xml 268 272 <span type="species:ncbi:9913">calf</span>
###xml 663 667 <span type="species:ncbi:9913">calf</span>
Due to geometrical differences between histological cross-sections of vastus lateralis and gastrocnemius, our normal muscle was characterized with higher total receptor density (due to 11.3% higher myocyte volume fraction, Table 1) than that in calf muscle, while our calf muscle was characterized with higher total matrix site density (due to 8% larger available interstitial fluid volume fraction, Table 1) than that in normal muscle. Therefore the normal compartment had higher amount of total extracellular VEGF121 (mostly surface receptor-bound), but lower amounts of total extracellular VEGF165 and sVEGFR1 (mostly matrix-bound), per tissue volume than the calf compartment (Fig. S1-B,C,D).
###end p 150
###begin title 151
iv. Occupancy of matrix sites
###end title 151
###begin p 152
###xml 183 186 183 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 252 265 252 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-E,F,G</xref>
###xml 126 130 <span type="species:ncbi:9913">calf</span>
The fractional occupancies of total matrix sites were uniformly minute across ECM, EBM and PBM, as well as between normal and calf compartments (differences <0.001%) - only 0.04% VEGF165-occupied and 0.15% sVEGFR1-occupied - leaving 99.81% unoccupied (Fig. S1-E,F,G). These fractional occupancies remained characteristically low (<0.6%) throughout sensitivity analyses.
###end p 152
###begin title 153
v. Occupancy of VEGFRs and NRP1
###end title 153
###begin p 154
###xml 223 232 223 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-H</xref>
###xml 289 298 289 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-I</xref>
###xml 372 375 372 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 386 389 386 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 499 502 499 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 529 532 529 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 540 549 540 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1-J</xref>
###xml 94 98 <span type="species:ncbi:9913">calf</span>
The fractional occupancies of total surface receptors were also consistent between normal and calf compartments (differences <1%): (i) total VEGFR1 were 26% free, 66% NRP1-coupled but not VEGF-ligated, and 8% VEGF-ligated (Fig. S1-H); (ii) total VEGFR2 were 80% free and 20% VEGF-ligated (Fig. S1-I); (iii) total NRP1 were 16% free, 0.3% sVEGFR1-bound with or without VEGF121, 0.1% VEGF165-bound, 66% coupled to unactivated VEGFR1 (i.e., VEGFR1-NRP1), and 18% coupled to signaling VEGFRs (i.e., VEGF121-VEGFR1-NRP1 or VEGFR2-VEGF165-NRP1) (Fig. S1-J).
###end p 154
###begin title 155
###xml 32 36 <span type="species:ncbi:9913">calf</span>
1.3. Physiological variation in calf volume-of-interest
###end title 155
###begin p 156
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 54 58 <span type="species:ncbi:9913">calf</span>
###xml 395 399 <span type="species:ncbi:9913">calf</span>
###xml 485 491 <span type="species:ncbi:9913">calves</span>
###xml 531 535 <span type="species:ncbi:9913">calf</span>
Within a threefold increase in volume of the "healthy calf muscle" compartment (up to 2,604 cm3), along with corresponding decreases in the "normal compartment" volume (down to 58,717 cm3), all control predictions of VEGF and sVEGFR1 distributions remained consistent (to within 1%), while receptor occupancy profiles remain unchanged. This implied that in cases that require modeling of bigger calf regions-of-interest, such as to include the tibialis anterior, or to study bilateral calves, the geometric differences between our calf vs. normal muscle parameterizations would not cause deviations in the overall baseline healthy profile attained by the stated set of control secretion rates.
###end p 156
###begin title 157
1.4. Basal concentration gradients & flow profiles
###end title 157
###begin p 158
###xml 0 6 0 6 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
Fig. 4 summarizes the inter- and intra-compartmental flow balance of soluble species at basal secretion rates; as will be shown in subsequent sections, the net directions and relative magnitudes of these mass flows dictated how the system responded to parameter perturbations. A key difference was noted between the VEGF and sVEGFR1 flows at steady state: most interstitial VEGF was internalized locally, via complex formation with abluminal VEGFRs, before it had a chance to permeate into the plasma, contributing to its lower plasma concentrations; whereas interstitial sVEGFR1, apart from its abluminal internalization, had an equally significant route of escape via lymph flow which contributed to its higher plasma concentration. Consequently, the transendothelial (plasma vs. interstitial) concentration gradients were differentially established, such that free VEGF and sVEGFR1-VEGF complexes experienced net intravastion (IS to plasma) at control, while free sVEGFR1 had an overall tendency to extravasate (plasma to IS) at control. Integral to the flow balances were the net mass transfers between the three soluble species: interstitially, the steady-state inflows for both free VEGF and sVEGFR1 outweighed their respective outflows, signifying a net tendency for them to associate and form sVEGFR1-VEGF complexes; in the plasma, the steady-state inflows for VEGF and sVEGFR1 were less than their respective outflows, indicative of an additional source from net dissociation of sVEGFR1-VEGF complexes.
###end p 158
###begin title 159
Basal Steady-State Flow Profiles of Free VEGF (left), sVEGFR1-VEGF Complexes (middle), Free sVEGFR1 (right).
###end title 159
###begin p 160
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Solid-colored arrows</italic>
###xml 245 264 245 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Color-graded arrows</italic>
Solid-colored arrows represent intra-compartmental flows (i.e., secretion, internalization) and inter-compartmental flows (i.e., net vascular permeability, lymph flow, plasma clearance), with their relative magnitudes reflected by arrow widths. Color-graded arrows between columns indicate mass transfer flows between species (i.e., net association of free VEGF and free sVEGFR1 to form sVEGFR1-VEGF complexes, or net dissociation of the complex back into its constituents).
###end p 160
###begin title 161
2. Increasing VEGF- or sVEGFR1-secretion rates did not systemically lower free sVEGFR1 or free VEGF concentrations respectively
###end title 161
###begin title 162
2.1. System sensitivity to VEGF-secretion rates
###end title 162
###begin p 163
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A</xref>
###xml 101 110 101 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Normal</sub>
###xml 101 110 101 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Normal</sub></italic>
###xml 118 125 118 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 203 219 203 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 225 239 225 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 267 269 267 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 267 269 267 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 451 457 451 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
###xml 468 470 468 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 468 470 468 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 514 523 514 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF</sub>
###xml 556 565 556 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF</sub>
###xml 651 653 651 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 651 653 651 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 685 701 685 701 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 730 744 730 744 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 851 857 851 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
###xml 121 125 <span type="species:ncbi:9913">Calf</span>
###xml 235 239 <span type="species:ncbi:9913">Calf</span>
###xml 740 744 <span type="species:ncbi:9913">Calf</span>
###xml 845 849 <span type="species:ncbi:9913">calf</span>
First we examined the VEGF response to increasing VEGF-secretion rates as illustrated in Fig. 2A. [V]IS,Normal and [V]IS,Calf were essentially determined by their respective local VEGF secretion rates, qTotalVEGF,Normal and qTotalVEGF,Calf. This was expected with [V]IS, since the intracompartmental flows (secretion and internalization) of VEGF dominated over its intercompartmental flows (vascular permeability and lymphatic drainage) in magnitude (Fig. 4). Thus [V]IS was greatly sensitive to local changes in qTotalVEGF, but relatively insensitive to qTotalVEGF of the other compartment due to weak intercompartmental communication. Similarly, [V]pl was increasingly dependent on qTotalVEGF,Normal but largely insensitive to qTotalVEGF,Calf, following the much larger intravasation flow from the normal compartment relative to that from the calf (Fig. 4).
###end p 163
###begin p 164
###xml 143 157 143 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Calf</sub>
###xml 200 206 200 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
###xml 223 230 223 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 293 300 293 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 293 300 293 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 332 339 332 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A</xref>
###xml 456 458 456 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 456 458 456 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 467 476 467 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Normal</sub>
###xml 467 476 467 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Normal</sub></italic>
###xml 530 546 530 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF,Normal</sub>
###xml 578 587 578 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Normal</sub>
###xml 578 587 578 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Normal</sub></italic>
###xml 614 617 614 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 843 852 843 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Normal</sub>
###xml 843 852 843 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Normal</sub></italic>
###xml 862 869 862 869 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 862 869 862 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 880 882 880 882 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 880 882 880 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 884 891 884 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A</xref>
###xml 1095 1102 1095 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s001">Fig. S1</xref>
###xml 153 157 <span type="species:ncbi:9913">Calf</span>
###xml 226 230 <span type="species:ncbi:9913">Calf</span>
###xml 296 300 <span type="species:ncbi:9913">Calf</span>
###xml 865 869 <span type="species:ncbi:9913">Calf</span>
###xml 933 937 <span type="species:ncbi:9913">calf</span>
On the other hand, sVEGFR1 concentrations were affected by VEGF-secretion rates in two asymmetrical ways. Firstly, the response to increasing qTotalVEGF,Calf was expected from previous flow analysis (Fig. 4): a surge in [V]IS,Calf was compensated by increased complex formation, lowering [sR1]IS,Calf in the process of association (Fig. 2A). Subsequent intravasation of sVEGFR1-VEGF complexes and their dissociation in plasma was too modest to affect [sR1]pl or [sR1]IS,Normal. A second mode of response occurred with increasing qTotalVEGF,Normal, beginning with an elevated [V]IS,Normal which promoted VEGFR2-VEGF165-NRP1 formation, thereby diminishing the availability of free NRP1 to bind free sVEGFR1. As a result of decreased sVEGFR1-internalization via NRP1-complexes, interstitial free sVEGFR1 actually increased globally (in both [sR1]IS,Normal and [sR1]IS,Calf) via [sR1]pl (Fig. 2A). The asymmetry was a consequence of the calf compartment having less endothelial surface area per volume and thus lower total surface receptor densities than the normal muscle compartment (supplemental Fig. S1), such that the second mechanism involving NRP1-VEGFR2 coupling was not sizeable enough to override the first mechanism involving sVEGFR1-VEGF association.
###end p 164
###begin p 165
###xml 130 132 130 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 130 132 130 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 160 169 160 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TotalVEGF</sub>
###xml 225 232 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2B</xref>
Lastly, the density of VEGF-ligated signaling complexes on the abluminal surface of the endothelium positively correlated with [V]IS. Consequently, increasing qTotalVEGF intensified both VEGFR1 and VEGFR2 signaling profiles (Fig. 2B).
###end p 165
###begin title 166
2.2. System sensitivity to sVEGFR1-secretion rates
###end title 166
###begin p 167
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig. 3A</xref>
###xml 95 104 95 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Normal</sub>
###xml 95 104 95 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Normal</sub></italic>
###xml 114 121 114 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 207 217 207 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Normal</sub>
###xml 223 231 223 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Calf</sub>
###xml 282 288 282 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
###xml 459 461 459 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 459 461 459 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 500 503 500 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 649 651 649 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 649 651 649 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 661 663 661 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 661 663 661 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 696 706 696 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Normal</sub>
###xml 759 761 759 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 759 761 759 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 846 853 846 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 846 853 846 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 886 896 886 896 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Normal</sub>
###xml 976 983 976 983 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Calf</sub>
###xml 976 983 976 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Calf</sub></italic>
###xml 1031 1041 1031 1041 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Normal</sub>
###xml 1076 1084 1076 1084 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1,Calf</sub>
###xml 1106 1115 1106 1115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS,Normal</sub>
###xml 1106 1115 1106 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS,Normal</sub></italic>
###xml 1226 1228 1226 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 1226 1228 1226 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1320 1323 1320 1323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR1</sub>
###xml 1325 1331 1325 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig 3B</xref>
###xml 1373 1375 1373 1375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 1373 1375 1373 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 117 121 <span type="species:ncbi:9913">Calf</span>
###xml 227 231 <span type="species:ncbi:9913">Calf</span>
###xml 849 853 <span type="species:ncbi:9913">Calf</span>
###xml 979 983 <span type="species:ncbi:9913">Calf</span>
###xml 1080 1084 <span type="species:ncbi:9913">Calf</span>
###xml 1188 1192 <span type="species:ncbi:9913">calf</span>
Fig. 3A illustrates the VEGF and sVEGFR1 responses to increasing sVEGFR1-secretion rates. [sR1]IS,Normal and [sR1]IS,Calf were predicted to most significantly depend on their local sVEGFR1-secretion rates, qsR1,Normal and qsR1,Calf respectively, in a linear fashion. Flow analysis (Fig. 4) suggested that the elevated interstitial free sVEGFR1 would then associate with free VEGF to form sVEGFR1-VEGF complexes, which accounted for the slight decreases in [V]IS in the direction of increasing local qsR1. Furthermore, the complexes formed in the interstitium were expected to intravasate and dissociate in the plasma, as confirmed by the rise in [V]pl and [sR1]pl in the direction of increasing qsR1,Normal. The cycle completes with part of the elevated [sR1]pl extravasating back into the interstitium, hence accounting for the increase in [sR1]IS,Calf in the direction of increasing qsR1,Normal. Thus unlike VEGF in the previous subsection, interstitial sVEGFR1 (e.g., [sR1]IS,Calf) was able to respond to distal changes (e.g., qsR1,Normal). The asymmetry where increasing qsR1,Calf did not elevate [sR1]IS,Normal was due to the fact that the intravasation flow of the complex from the calf was insufficient to elevate [sR1]pl on its own. Finally, the signaling profiles did not change significantly as a function of qsR1 (Fig 3B), reflective of the minute changes in [V]IS already described.
###end p 167
###begin title 168
3. Receptor densities and ratios affected plasma and interstitial concentrations of VEGF and sVEGFR1, as well as surface-bound VEGFR occupancy
###end title 168
###begin p 169
###xml 426 433 426 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
###xml 1043 1052 1043 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5B&#8211;D</xref>
Receptor densities and ratios were varied over two orders of magnitude about the healthy control values, while keeping VEGF- and sVEGFR1-secretion rates fixed, in a steady-state sensitivity analysis to predict system response to physiological/pathological regulation of receptor expression levels. Interstitial and plasma concentrations of free VEGF and free sVEGFR1 were found to be sensitive over most of the tested ranges (Fig. 5A), as described in further mechanistic detail below. Overall, increasing NRP1 density, increasing VEGFR2:VEGFR1 ratio (denoted as [R2]/[R1]), and decreasing total VEGFR density all steepened plasma vs. interstitium gradients (i.e., farther from 1:1) for VEGF concentrations; while increases in all three parameters reduced sVEGFR1 gradients (i.e., closer to 1:1). In addition, higher NRP1 density or [R2]/[R1] favored a net shift towards pro-angiogenic signaling; while total VEGFR densities within the same order of magnitude as NRP1 density were predicted to be optimal for overall pro-angiogenic signaling (Fig. 5B-D).
###end p 169
###begin title 170
Steady-State Sensitivity to Receptor Density.
###end title 170
###begin p 171
###xml 669 672 669 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 687 690 687 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 498 502 <span type="species:ncbi:9913">calf</span>
A. Sensitivity of plasma and interstitial concentrations of free VEGF, free sR1, and sR1-VEGF complex to NRP1 density (3 surfaces), VEGFR1:VEGFR2 density ratio (x-axis), and total VEGFR density (y-axis). B-D. Sensitivity of signaling complex distribution to NRP1 density (B), ratio of VEGFR2:VEGFR1 density ratio (C), and total VEGFR density (D). Bracketed percentages are VEGF-bound fractional occupancies of total VEGFR1 (left) and total VEGFR2 (right), averaged (range <0.9%) between normal and calf compartments. E. Sensitivity of NRP1 distribution to total VEGFR density. '+' = control; 'max' and 'min' bound targeted ranges; 'EC' = endothelial cell; 'V121' = VEGF121; 'V165' = VEGF165; 'R1' = VEGFR1; 'sR1' = sVEGFR1; 'R2' = VEGFR2.
###end p 171
###begin title 172
3.1. Sensitivity to neuropilin-1 density
###end title 172
###begin p 173
###xml 178 181 178 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 192 195 192 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 220 223 220 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 312 319 312 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
###xml 468 475 468 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
###xml 670 677 670 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
Higher NRP1 densities were generally associated with lower concentrations of all soluble species, since NRP1 was a vehicle for internalizing VEGF and sVEGFR1 via endothelial VEGF121-NRP1, VEGF165-NRP1, sVEGFR1-NRP1, VEGF121-VEGFR1-NRP1 complexes. For free VEGF, this was most evident at low total VEGFR density (Fig. 5A), when the alternative internalization route for VEGF via VEGFR was minimized. For free sVEGFR1, this was most evident at high total VEGFR density (Fig. 5A), when free VEGF remained low to reduce the secondary effects of sVEGFR1-VEGF complex formation. Secondarily, declines in sVEGFR1-VEGF complex concentrations followed increases in NRP1 density (Fig. 5A), as NRP1 competed with sVEGFR1 for binding with free VEGF.
###end p 173
###begin p 174
###xml 82 89 82 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5B</xref>
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 395 398 395 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 409 416 409 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5B</xref>
###xml 608 611 608 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 653 656 653 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 925 929 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
Moreover, increasing NRP1 density shifted the VEGF-signaling profiles as shown in Fig. 5B. The overall drop in "anti-angiogenic potential", as represented by ligated VEGFR1 complexes, can be explained by NRP1's high affinity for VEGFR1. At 105 NRP1/EC, almost all (97%) VEGFR1 became part of unligated VEGFR1-NRP1 complexes - a shift that dramatically reduced the availability of VEGFR1 for VEGF165-ligation (Fig. 5B). On the other hand, the overall rise in "pro-angiogenic potential", as represented by ligated VEGFR2 complexes, can be explained by NRP1's role as a co-receptor in presenting NRP1-bound VEGF165 to VEGFR2, as well as in stabilizing VEGF165-VEGFR2 through their triplet configuration. All together, these synergistic functions of NRP1 in reducing anti-angiogenic complexes and promoting pro-angiogenic complexes, were in tune with computational predictions from our previous studies in the absence of sVEGFR1 [54].
###end p 174
###begin title 175
3.2. Sensitivity to VEGFR2:VEGFR1 density ratio ([R2]/[R1])
###end title 175
###begin p 176
###xml 343 350 343 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
Although higher NRP1 density in general lowered free VEGF concentrations predominantly through enhanced internalization of VEGF-bound NRP1, exceptions were noted in the region of low [R2]/[R1] (<1), roughly between 10,000 to 20,000 total VEGFR/EC, where free VEGF concentrations were apparently higher at 10,000 NRP1/EC than at 1,000 NRP1/EC (Fig. 5A). In this region, the greater abundance of VEGFR1 gave more prominence to NRP1's tendency to competitively shift the distribution of total VEGFR1 towards formation of unligated VEGFR1-NRP1 complexes, in the process freeing VEGF that had been bound to uncoupled VEGFR1, hence elevating free VEGF concentrations.
###end p 176
###begin p 177
###xml 176 183 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
###xml 281 284 281 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 362 365 362 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 381 384 381 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 424 427 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 437 444 437 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5C</xref>
###xml 461 464 461 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 541 544 541 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 567 570 567 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 606 609 606 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 619 626 619 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5C</xref>
###xml 733 736 733 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 741 744 741 744 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
For the independent increase of [R2]/[R1] while fixing total receptors at control densities, the following concentration changes were observed in all three fluid compartments (Fig. 5A), originating from the tissues' interstitial fluids and propagated into the plasma: (i) free VEGF121 increased - due to a net decrease in internalization force (reduction in VEGF121-VEGFR1 and VEGF121-VEGFR1-NRP1 outweighed increase in VEGF121-VEGFR2) (Fig. 5C); (ii) free VEGF165 decreased - due to a net increase in internalization force (increase in VEGF165-VEGFR2 and VEGFR2-VEGF165-NRP1 overshadowed reduction in VEGF165-VEGFR1) (Fig. 5C); (iii) an overall decrease in free total VEGF - despite an increasing fraction of isoform 121 (up to VEGF121:VEGF165 = 1:3 at [R2]/[R1] = 10); and (iv) free sVEGFR1 decreased - due to dissociation of NRP1 from VEGFR1-NRP1 complexes to become available for sVEGFR1-binding and internalization (data not shown).
###end p 177
###begin title 178
3.3. Sensitivity to total VEGFR density ([R1]+[R2])
###end title 178
###begin p 179
###xml 249 256 249 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
###xml 1067 1074 1067 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5D</xref>
Our simulations presented several theoretical indications that the VEGF/sVEGFR1 system has optimal operating range around the VEGFR1:VEGFR2:NRP1 receptor density ratio of 1:1:1. Firstly, in examining the free sVEGFR1 concentration surfaces shown in Fig. 5A, the region of maximal or linear gain for each surface always spanned total VEGFR densities near the same order of magnitude as NRP1 density. In fact, the sVEGFR1 concentration surfaces for 10,000 NRP1/EC were not only sigmoidal over the examined total VEGFR density range, centered about [R1]+[R2] = 20,000/EC, they were also sigmoidal in the direction of VEGFR ratio, centered about 1:1. Similarly, of the free VEGF concentration surfaces, the sigmoidal surface for 10,000 NRP/EC had the closest operating range over [R1]+[R2] = 20,000/EC. A second indication was based on the observation that the formation of signaling VEGFR2 complexes was biphasic in the direction of total VEGFR density, allowing the most efficient net "pro-angiogenic potential" to be reached within the order of 10,000 total VEGFR/EC (Fig. 5D).
###end p 179
###begin p 180
###xml 92 99 92 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5D</xref>
###xml 501 508 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5D</xref>
###xml 681 688 681 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5E</xref>
###xml 796 799 796 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 813 816 813 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 931 938 931 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5D</xref>
###xml 997 1000 997 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1007 1014 1007 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5D</xref>
###xml 1154 1157 1154 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1204 1211 1204 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5E</xref>
###xml 1287 1290 1287 1290 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1349 1358 1349 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5D,E</xref>
Mechanistically, the dependence of signaling profiles on total VEGFR density as depicted in Fig. 5D could be explained by two forces: (1) the direct effects of the sheer increase in number of VEGFRs available for VEGF ligation; (2) the indirect effects of VEGFR's density ratio relative to NRP1 which was fixed at 10,000/EC. The former effects increased quantities of non-NRP1-coupled VEGF-VEGFR complexes with increasing total VEGFR density, despite the diminishing fractional occupancies of VEGFRs (Fig. 5D). The latter effects stemmed from an increasing proportion of total NRP1 being used up in formation of unligated VEGFR1-NRP1 complexes with increasing total VEGFR density (Fig. 5E). This meant that the higher the total VEGFR density, the less free NRP1 were available to form VEGFR2-VEGF165-NRP1 and VEGF121-VEGFR1-NRP1, hence the generally decreasing contribution of these species in their respective signaling profiles (Fig. 5D). The opposing trend in the biphasic nature of VEGFR2-VEGF165-NRP1 (Fig. 5D) came from the fact that at very low total VEGFR density, quantities of VEGFR2 were so limited that there was an unusual population of VEGF165-NRP1 left at steady state for 2,000 VEGFR/EC (Fig. 5E) with no VEGFR2 to present to. Thus explained the quick jump in VEGFR2-VEGF165-NRP1 as soon as VEGFR2 were available at 10,000 VEGFR/EC (Fig. 5D,E).
###end p 180
###begin title 181
###xml 115 118 115 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
4. VEGFRs' affinities for VEGF affected free sVEGFR1 concentrations via NRP1 availability; NRP1's affinity for VEGF121 was inconsequential
###end title 181
###begin p 182
This section explores system sensitivity to the effective (microenvironment-dependent) dissociation constants of VEGF from its receptors over the wide ranges reported in literature.
###end p 182
###begin title 183
4.1. Sensitivity to VEGF-binding affinity of VEGFR1 and VEGFR2
###end title 183
###begin p 184
###xml 242 249 242 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6A</xref>
###xml 456 463 456 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6B</xref>
###xml 700 703 700 703 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 720 727 720 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6A</xref>
###xml 757 760 757 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 865 872 865 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6C</xref>
The shifts in signaling profiles were as expected from the competitive binding of VEGF between VEGFRs: increasing one VEGFR's VEGF-affinity boosted formation of its signaling complexes to the detriment of the other VEGFR's complex formation (Fig. 6A). As for the soluble species, total free VEGF in all compartments decreased with increasing VEGF-binding affinity of either VEGFR1 or VEGFR2 - presumably through enhanced internalization of complexed VEGF (Fig. 6B). Free sVEGFR1 concentrations, however, changed in opposite directions: lowered with increasing VEGF-VEGFR1 affinity but rose with increasing VEGF-VEGFR2 affinity. The directional change in free sVEGFR1 thus followed that of VEGFR2-VEGF165-NRP1 complexes (Fig. 6A) - i.e., the more VEGFR2-VEGF165-NRP1 complexes formed, the less unbound NRP1 available for binding and internalization of free sVEGFR1 (Fig. 6C).
###end p 184
###begin title 185
Steady-State Sensitivity to VEGF-Binding Affinities of Cell Surface Receptors: VEGFR1, VEGFR2 and NRP1.
###end title 185
###begin p 186
###xml 424 427 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 752 753 752 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 810 811 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 863 866 863 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 871 874 871 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 709 713 <span type="species:ncbi:9913">calf</span>
A. Higher VEGF-VEGFR1 affinity and VEGF-VEGFR2 affinity respectively shifted the signaling profile towards anti- and pro-angiogenic complexes. B. Free VEGF levels lowered with increasing VEGF-binding affinity of either VEGFR1 or VEGFR2; while free sVEGFR1 levels rose and fell with increasing VEGF-VEGFR1 and VEGF-VEGFR2 affinity respectively. C. Availability of unbound NRP1 changed inversely with the amount of VEGFR2-VEGF165-NRP1 formed. Free VEGF and sVEGFR1 levels (D), as well as signaling profiles (E), were largely insensitive to NRP1's direct binding-affinity with VEGF. Bracketed percentages in A and D are VEGF-bound fractional occupancies of total VEGFR, averaged (range <0.3%) between normal and calf compartments. '+'/'Ctrl' = control; 'Kd(V,R)' = dissociation constant between VEGF and VEGFR; 'Kd(V121/V165,N)' = dissociation constants between VEGF121/VEGF165 and NRP1; 'R1' = VEGFR1; 'sR1' = sVEGFR1; 'R2' = VEGFR2.
###end p 186
###begin title 187
4.2. Sensitivity to VEGF-binding affinity of NRP1
###end title 187
###begin p 188
###xml 33 36 33 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 72 75 72 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 207 214 207 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6D</xref>
###xml 310 313 310 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 399 402 399 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 409 416 409 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6D</xref>
###xml 465 468 465 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 511 514 511 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 588 595 588 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6E</xref>
###xml 646 649 646 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 677 684 677 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6D</xref>
Lowering NRP1's affinity for VEGF165 over two orders of magnitude - Kd(V165,N) from 200 pM to 25 nM -caused only opposing changes of up to 0.3% in the VEGF-bound fractional occupancies of VEGFR1 and VEGFR2 (Fig. 6D). The minute attenuation of pro-angiogenic potential reflected a declining availability of VEGF165-bound NRP1s for coupling with VEGFR2, hence the diminishing quantities of VEGFR2-VEGF165-NRP1 (Fig. 6D). Simultaneously in all fluid volumes, free VEGF121 levels remained consistent while free VEGF165, presumably released from NRP1s, elevated slightly (plasma data shown in Fig. 6E). This in turn increased availability of free VEGF165 for direct VEGFR1-binding (Fig. 6D).
###end p 188
###begin p 189
###xml 135 138 135 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 177 180 177 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 190 193 190 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 287 292 287 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Pan1">[105]</xref>
###xml 351 358 351 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6D</xref>
###xml 404 411 404 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">Fig. 6E</xref>
###xml 456 459 456 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 486 489 486 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 534 537 534 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 592 595 592 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 693 699 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 825 828 825 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 886 889 886 889 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
Our simulations also predicted inconsequential effects from incorporating the newly purported binding interaction between NRP1 and VEGF121. Specifically, when modeling both VEGF121- and VEGF165-affinities of NRP1 at the low affinities cited by Pan et al. (220 nM and 120 nM respectively [105]), there were no remarkable changes in signaling profiles (Fig. 6D) nor concentrations of free soluble species (Fig. 6E) compared to simulation results with no VEGF121-NRP1 binding but weak VEGF165-NRP1 binding. Furthermore, when keeping VEGF165-NRP1 affinity at control (320 pM) and introducing VEGF121-NRP1 binding at an affinity 1.83x higher than that (in accordance with the ratio reported by Pan et al.), all system distributions were almost identical to those at control - because even then, the steady-state population of VEGF121-NRP1 only represented an insignificant 0.7% of total VEGF121 in muscle tissues.
###end p 189
###begin p 190
Thus, as long as VEGF had a lower affinity to NRP1 than to VEGFRs, the system was largely insensitive to variations in the VEGF-binding affinities of NRP1. This suggested that mechanistically, the significance of NRP1 as a co-receptor in the VEGF system could be largely attributed to NRP1's strength in coupling VEGFRs rather than its direct affinity for VEGF.
###end p 190
###begin title 191
###xml 105 108 105 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
5. Densities and VEGF-affinity of interstitial matrix sites affected only matrix-bound reservoirs of VEGF165 and sVEGFR1
###end title 191
###begin p 192
###xml 268 274 268 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g007">Fig. 7</xref>
###xml 325 328 325 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 402 411 402 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g007">Fig. 7A,B</xref>
###xml 454 457 454 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 496 499 496 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 526 533 526 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g007">Fig. 7A</xref>
###xml 608 611 608 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 809 812 809 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 851 852 851 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 850 852 850 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 856 859 856 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Steady-state analyses showed that fluctuations in the VEGF-binding affinity and densities of interstitial matrix sites had no detectable effects on the concentrations of all soluble species (in both plasma and interstitial fluid), nor on surface receptor occupancies (Fig. 7). In contrast, the quantities of matrix-bound VEGF165 and sVEGFR1 increased drastically with increasing matrix site densities (Fig. 7A,B); while the matrix-bound reservoir of VEGF165 also grew drastically with higher VEGF165-affinity of matrix sites (Fig. 7A). Whereas these effects culminated into several-fold changes in total VEGF165 and sVEGFR1 in muscle tissues, the fractional occupancy of total matrix sites remained very low (at a consistent 0.19% irrespective of matrix site densities) and changing minutely with varying VEGF165-affinity (up to 0.55% at 10x control Kd(M,V165).
###end p 192
###begin title 193
###xml 84 87 84 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Sensitivity to Density & VEGF-Binding Affinity of Interstitial Matrix Sites for VEGF165 & sVEGFR1.
###end title 193
###begin p 194
###xml 32 35 32 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 158 161 158 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 260 261 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 367 370 359 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 398 401 390 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 444 447 436 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 460 463 452 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 483 486 475 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 574 577 566 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 601 604 593 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 648 649 640 641 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 722 725 714 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 934 937 926 929 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 113 117 <span type="species:ncbi:9913">calf</span>
Steady-state sensitivity of VEGF165 (A) and sVEGFR1 (B) distributions in blood (top), normal tissue (middle) and calf tissue (bottom) compartments to the VEGF165-binding affinity (Kd(M,V)) and densities ([ECM]; [BM]) of interstitial matrix sites. At control: Kd(M,V) = 23.8 nM; [ECM] = 20 microM; [BM] = 0.75 microM. Concentrations of soluble species (e.g., free VEGF165, free sVEGFR1, sVEGFR1-VEGF165) and surface VEGFR occupancies (e.g., VEGF165-VEGFR1, VEGF165-VEGFR2, VEGFR2-VEGF165-NRP1) were completely insensitive; whereas the sizes of matrix-bound reservoirs of VEGF165 and sVEGFR1 (e.g., VEGF165-ECM, sVEGFR1-PBM) were greatly affected. 'Kd(M,V)' = dissociation constant between interstitial matrix sites and VEGF165; '[ECM]' and '[BM]' = densities of binding sites for VEGF or sVEGFR1 in extracellular matrix and basement membranes respectively'; 'Ctrl' = control; 'PBM' = parenchymal BM; 'EBM' = endothelial BM; V165 = VEGF165; 'R1' = VEGFR1; 'sR1' = sVEGFR1; 'R2' = VEGFR2.
###end p 194
###begin title 195
6. Transport parameters affected concentrations of plasma VEGF, plasma sVEGFR1 and interstitial sVEGFR1, but not surface-bound VEGFR occupancy
###end title 195
###begin p 196
###xml 356 357 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 355 357 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 464 471 464 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g008">Fig. 8A</xref>
###xml 486 487 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 485 487 485 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 545 552 545 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9A</xref>
###xml 573 575 573 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 572 575 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
###xml 641 648 641 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g010">Fig. 10</xref>
Transport parameters were independently varied over two orders of magnitude about control for sensitivity analysis. In plasma, steady-state concentrations of all soluble species were strongly dependent on transport rates, whereas in the interstitium, sVEGFR1 concentration was much more sensitive than VEGF to transport parameters. In general: increasing kP reduced plasma vs. interstitium gradients (i.e., closer to 1:1) for both VEGF and sVEGFR1 concentrations (Fig. 8A); increasing kL lessened VEGF gradients but steepened sVEGFR1 gradients (Fig. 9A); while decreasing kCL reduced VEGF gradients without much effect on sVEGFR1 gradients (Fig. 10). Additionally, the current model showed that physiological fluctuations in transport parameters were ineffective in altering endothelial VEGFR occupancy, given their minute effect on interstitial free VEGF levels.
###end p 196
###begin title 197
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 43 45 43 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
Steady-State Effects of Permeability Rate (kP) on VEGF and sVEGFR1 Concentrations (A) & Flows (B).
###end title 197
###begin p 198
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 28 30 28 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 272 274 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 300 308 300 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P,Normal</sub>
###xml 299 308 299 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P,Normal</sub></italic>
###xml 434 438 <span type="species:ncbi:9913">calf</span>
In general, with increasing kP, concentrations changed in the directions that reduced transendothelial gradients: (i) plasma VEGF concentration increased; (ii) plasma sVEGFR1 decreased and interstitial sVEGFR1 increased. Exceptions were observed with localized changes in kP - e.g., increasing only kP,Normal from 'supine(ctrl)' to 'fenestration' enhanced sVEGFR1 extravasation into the normal compartment in expense of that into the calf, causing non-uniform changes in interstitial sVEGFR1 concentrations (increased locally, decreased distally). 'Lo' = low; 'Dep' = dependent; '+' = supine (control); 'Ex' = exercise; 'Fen' = fenestration; 'H' = high.
###end p 198
###begin title 199
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 62 64 62 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
Steady-State and Dynamic Effects of Lymphatic Drainage Rates (kL).
###end title 199
###begin p 200
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 0 61 0 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Steady-state effects of k<sub>L</sub> on VEGF and sVEGFR1 concentrations</italic>
###xml 66 75 66 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">and flows</italic>
###xml 117 118 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 121 122 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 125 127 125 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 141 143 141 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 407 408 407 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 406 408 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 439 447 439 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L,Normal</sub>
###xml 438 447 438 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L,Normal</sub></italic>
###xml 785 786 785 786 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 784 786 784 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 993 994 993 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 973 1040 973 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dynamic Effects of k<sub>L</sub> on VEGF, sVEGFR1, and sR1-VEGF Concentrations</italic>
###xml 1047 1048 1047 1048 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1046 1048 1046 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 1456 1457 1456 1457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1455 1457 1455 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 1771 1772 1771 1772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1770 1772 1770 1772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 1887 1893 1887 1893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 902 906 <span type="species:ncbi:9913">calf</span>
###xml 1681 1685 <span type="species:ncbi:9913">Calf</span>
###xml 1792 1796 <span type="species:ncbi:9913">calf</span>
Steady-state effects of kL on VEGF and sVEGFR1 concentrations (A) and flows (B). Of the three transport parameters (kP, kL, kCL), increasing kL over two orders of magnitude about the control value resulted in the greatest fluctuations in steady-state concentrations: most significantly elevating plasma VEGF and sVEGFR1, while lowering interstitial sVEGFR1. Exceptions were noted with localized changes in kL - e.g., with increasing only kL,Normal from 'CP' to 'PE', the enhanced flushing of sVEGFR1 from the local interstitium into the plasma eventually spilled over through increased sVEGFR1 extravasation into the opposite compartment to elevate interstitial sVEGFR1 concentration there. In addition, a reversal in permeability flow of sVEGFR1-VEGF complex (red box) was noted for kL above control. 'Lo' = low; 'Nite' = night; '+' = supine awake (control); 'SE' = whole-body steady exercise; 'CP' = calf-only peak exercise; 'PE' = whole-body peak exercise; 'Hi' = high. Dynamic Effects of kL on VEGF, sVEGFR1, and sR1-VEGF Concentrations (C). kL-driven fluctuations in VEGF and sVEGFR1 attained within physiological diurnal cycles were less than those attained during steady-state analyses but still were of very wide ranges. "Bed-rest days" (purple columns) consisted of 15 hrs of wakefulness limited to supine or sitting postures, followed by 9 hrs of sleep. "Active days" (yellow columns) consisted of 15-hrs of activity starting off with a peak in kL during early exercise and settling down to a steady running/walking rate, followed by 9 hrs of sleep. Reversed permeability flow of sVEGFR1-VEGF complex (red cross-hatching) was observed in the latter active waking hours. "Calf-limited activity days" (aqua column) are same as "bed-rest days" except that active kL was induced in the calf during the first 15 hrs of wakefulness. Stick-figure illustrations adapted from Olszewski et al. Lymphology 1977, 10(3):178-183.
###end p 200
###begin title 201
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 47 50 47 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
Steady-state Effects of Plasma Clearance Rate (kCL) on VEGF and sVEGFR1 Concentrations.
###end title 201
###begin p 202
###xml 12 14 12 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 11 14 11 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
Increasing kCL resulted in: (i) drastically lower plasma concentrations of both free VEGF and sVEGFR1, (ii) lower interstitial sVEGFR1 but unchanged interstitial VEGF, and (iii) reduced transendothelial gradient for VEGF but not for sVEGFR1.
###end p 202
###begin title 203
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 58 60 58 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
6.1. Steady-state effects of vascular permeability rates (kP)
###end title 203
###begin p 204
###xml 15 16 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 14 16 14 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g008">Fig. 8A</xref>
###xml 120 127 120 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g008">Fig. 8B</xref>
###xml 230 231 230 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 229 231 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 608 609 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 607 609 607 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 752 753 752 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 751 753 751 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 900 906 900 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g008">Fig. 8</xref>
The effect of kP on free VEGF and sVEGFR1 concentrations (Fig. 8A) could be explained by their associated flow changes (Fig. 8B). Firstly, since the transendothelial VEGF gradient at control favored net intravasation, increasing kP resulted in significantly higher plasma concentrations of free VEGF. Interstitially, the corresponding decreases in free VEGF were insignificant, as the change in VEGF's transvascular flow was still overshadowed in magnitude by its secretion and internalization flows. Secondly, the transendothelial gradient of sVEGFR1 at control favored net extravasation, hence increasing kP resulted in: lower plasma concentrations of free sVEGFR1; as well as increased free sVEGFR1 in the interstitium facing the endothelium where kP was upregulated, at the expense of a decrease in interstitial free sVEGFR1 in the other tissue compartment (e.g., "Control" vs. "Fenestration" in Fig. 8).
###end p 204
###begin p 205
###xml 211 212 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 210 212 210 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 619 620 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 618 620 618 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
VEGF and sVEGFR1 distribution changes were also more drastic in blood than in interstitia. In the blood, the number of complexed sVEGFR1-VEGF increased slightly (e.g., 1.5x from control) with increasing global kP (e.g., 10x from control). This was sufficient to elevate the fractional occupancy of total sVEGFR1 (e.g., +9%) despite decreasing free sVEGFR1; yet not enough to prevent overall reductions in bound fraction of total VEGF (e.g., -14%) because of the greater increase in free VEGF. In the interstitium, the fractional occupancies of VEGFR1 and VEGFR2 by VEGF decreased <0.5% within the 100-fold increase in kP tested.
###end p 205
###begin title 206
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 47 49 47 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
6.2. Steady-state effects of lymph flow rates (kL)
###end title 206
###begin p 207
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 11 13 11 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 86 93 86 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9A</xref>
###xml 148 155 148 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9B</xref>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 278 280 278 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 629 630 629 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 628 630 628 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 681 684 681 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L,N</sub>
###xml 680 684 680 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L,N</sub></italic>
###xml 738 745 738 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9A</xref>
###xml 1080 1081 1080 1081 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1079 1081 1079 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 1276 1283 1276 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9A</xref>
###xml 696 700 <span type="species:ncbi:9913">Calf</span>
###xml 898 902 <span type="species:ncbi:9913">calf</span>
###xml 1138 1142 <span type="species:ncbi:9913">calf</span>
Similarly, kL-driven changes in steady-state concentrations of free VEGF and sVEGFR1 (Fig. 9A) could be explained by their associated flow changes (Fig. 9B). Since lymph flow represented a unidirectional flushing of VEGF and sVEGFR1 from the interstitium into blood, increasing kL resulted in higher plasma and lower interstitial concentrations of free VEGF and sVEGFR1. All resulting differences were significant except for interstitial free VEGF, as lymphatic flow was also dwarfed by the secretion and internalization flows in the net balancing of VEGF entering and leaving the interstitia. It was noted that when increasing kL in one tissue compartment only (e.g., increasing kL,N only from "Calf Peak Exercise" to "Peak Exercise" in Fig. 9A), the interstitial concentration of free sVEGFR1 only decreased locally (e.g., normal), while slightly increased in the other tissue compartment (e.g., calf). This was due to a secondary "spill-over" of the elevated plasma free sVEGFR1 through increased extravasation into the distal compartment. This may suggest that if increasing kL were to be explored as a therapeutic means to alleviate calf tissue accumulation of sVEGFR1, local lymphatic flushing as induced by leg exercise may be more productive than whole-body exercise (Fig. 9A).
###end p 207
###begin p 208
###xml 139 140 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 138 140 138 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 500 501 500 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 499 501 499 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 540 547 540 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9B</xref>
###xml 671 672 671 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 670 672 670 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
Distribution changes were again more evident in the blood: the simultaneous elevations in free VEGF and sVEGFR1, due to increasing global kL (e.g., 10x from control), in turn synergistically increased sVEGFR1-VEGF complex formation (e.g., 88x from control), which elevated the complexed fractions of both VEGF (e.g., +13%) and sVEGFR1 (e.g., +8.7%). In addition, a reversal in permeability flow of sVEGFR1-VEGF complex, from net intravasation to net extravasation, was also observed upon increasing kL from control to steady exercise rate (Fig. 9B). In the interstitium, the fractional VEGF-occupancies of VEGFR1 and VEGFR2 decreased <1% within the 100-fold increase in kL tested.
###end p 208
###begin p 209
###xml 186 187 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 185 187 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
While steady-state analyses showed that plasma concentrations of sVEGFR1 and VEGF could vary up to 164 pM and 2.4 pM respectively (>150% about controls) over the physiological range of kL, we further examined whether concentration ranges of these magnitudes were attainable within physiological time-course.
###end p 209
###begin title 210
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 42 44 42 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
6.3. Dynamic effects of lymph flow rates (kL)
###end title 210
###begin p 211
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 47 49 47 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 125 132 125 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9C</xref>
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 176 178 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
A dynamic simulation of the diurnal changes of kL over a combination of "bed-rest days" and "active days", as illustrated in Fig. 9C, suggested that physiological variation of kL over the course of a day can still account for significant variation in plasma concentrations of VEGF and sVEGFR1. In blood, dynamic fluctuations in free sVEGFR1 always eclipsed that of free VEGF in amplitude, at up to 76 vs. 1.65 pM (approximately76% vs. 110% about controls). In the interstitia, diurnal ranges of VEGF and sVEGFR1 were much subdued compared to steady-state ranges: free VEGF varied up to 0.2 pM (approximately2% about controls), with negligible effects on VEGF-VEGFR complex formation; while free sVEGFR1 varied up to 2.5 pM (approximately7% about controls).
###end p 211
###begin p 212
###xml 349 350 349 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 348 350 348 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 403 405 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 411 418 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9C</xref>
###xml 653 654 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 652 654 652 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 719 720 719 720 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 718 720 718 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 1213 1220 1213 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9C</xref>
It was noted that sVEGFR1 equilibrated slower than VEGF, such that sVEGFR1 never fully re-established its steady state within the day, while VEGF reached its new steady state within hours. This differential characteristic time between VEGF and sVEGFR1 accounts for the unique responses of the three soluble species to activity-dependent changes in kL during "active days". From the waking hour (e.g., 48th h in Fig. 9C), plasma concentration of free sVEGFR1 followed a steady rise over the next 15 h before the onset of sleep. On the other hand, plasma free VEGF experienced a much steeper initial rise to a transient peak that closely accompanied the kL peak of early exercise, but soon falls into a lower plateau as kL also settled to its own steady state of normal activity. As for the sVEGFR1-VEGF complex in plasma, its steep initial peak and dip followed those of free VEGF, while a latter steady rise was driven by the persistent net influx of free sVEGFR1. In fact, plasma sVEGFR1-VEGF overtook interstitial sVEGFR1-VEGF at some point near the latter active hours of wakefulness, whereupon the permeability flow of the complex reversed in direction to become a net extravasation until the onset of sleep (Fig. 9C).
###end p 212
###begin p 213
In summary, a 15-h period of daytime activity could elevate plasma concentrations to 42 pM and 1.1 pM above control for free sVEGFR1 and VEGF respectively. However, 9 h of sleep was adequate for plasma free sVEGFR1 to fall back to below control levels regardless of whether the subject was active or inactive during waking hours (-32 pM after bed-rest vs. -16 pM after activity). Hence, consecutive "active days" negligibly enhanced the peak sVEGFR1 level attainable in subsequent "active days" (+44 pM sVEGFR1; +1.0 pM VEGF relative to control).
###end p 213
###begin title 214
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
6.4. Steady-state effects of plasma clearance rates (kCL)
###end title 214
###begin p 215
###xml 41 43 41 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
###xml 113 120 113 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g010">Fig. 10</xref>
Increasing direct clearance from blood (kCL) drastically lowered free VEGF and sVEGFR1 concentrations in plasma (Fig. 10). These primary effects in blood in turn were propagated into the interstitium through permeability, i.e., via reduced net sVEGFR1 extravasation and upregulated net VEGF intravasation. Consequently, interstitial concentrations of free sVEGFR1 were significantly lowered as well; though decreases in interstitial free VEGF were negligible, again because changes in intercompartmental flows were masked by the predominant secretion and internalization flows of VEGF.
###end p 215
###begin p 216
###xml 285 287 285 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
###xml 377 379 377 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CL</sub>
###xml 376 379 376 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>CL</sub></italic>
Distribution analysis in the blood showed that the number of sVEGFR1-VEGF complexes reduced proportionally to free VEGF (sVEGFR1-complexed fraction of total VEGF was consistent within 2%) while the fractional occupancy of sVEGFR1 dropped from 19% to 2% over the 100-fold variation in kCL. In the interstitium, the fractional VEGF-occupancies of VEGFRs decreased <0.2% for the kCL range tested.
###end p 216
###begin title 217
Discussion
###end title 217
###begin title 218
Healthy baseline: transendothelial gradients of VEGF and sVEGFR1
###end title 218
###begin p 219
###xml 53 62 53 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 460 462 460 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 460 462 460 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 520 522 520 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 520 522 520 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 731 733 731 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 731 733 731 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 748 750 748 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 748 750 748 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 842 847 830 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gavin1">[135]</xref>
###xml 849 854 837 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hoffner1">[136]</xref>
###xml 1168 1173 1156 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Arner1">[139]</xref>
###xml 1326 1335 1314 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
This paper documented our development of an original in silico multi-tissue model for simulating the systemic distributions of VEGF and sVEGFR1 for a healthy subject. The unexplained large variability in literature data of measured plasma concentrations of VEGF and sVEGFR1 in healthy subjects necessitates a thorough examination of inter-study differences in experimental protocol. Here in this study, we have chosen to target the plasma concentrations of [V]pl = 1.5 pM (converted for 46-kDa VEGF homodimers) and [sR1]pl = 100 pM (converted for 200-kDa sVEGFR1 homodimers). At the control secretion rates of VEGF and sVEGFR1 needed to reproduce these selected plasma concentrations, our predicted interstitial concentrations ([V]IS = 10 pM; [sR1]IS = 36 pM) were inconsistent with levels expected from microdialysis data (approximately1 pM [135], [136]). Technical concerns have been raised regarding the use of microdialysis membranes of high molecular-weight cut-offs to study macromolecules such as proteins, including compromised spatial resolutions associated with large probe sizes and unwanted ultrafiltration that could alter interstitial space compositions [139]. Until independent experimental validation for interstitial concentrations could be obtained using methods other than microdialysis, we propose several in silico assumptions-based sources of discrepancy between our predicted observations vs. microdialysis data for plasma VEGF below. They fall under these categories: (1) interstitium-to-blood transporters of VEGF; (2) blood sources of VEGF or sVEGFR1; (3) interstitial sinks of VEGF and sVEGFR1; and (4) organ subdivisions of body compartment.
###end p 219
###begin p 220
###xml 231 238 231 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 238 241 238 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hornig1">[8]</xref>
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ambati1">[16]</xref>
###xml 249 253 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Luttun1">[18]</xref>
###xml 281 283 281 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 353 355 353 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 353 355 353 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 372 378 372 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig. 3</xref>
###xml 433 439 433 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
###xml 889 891 889 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 889 891 889 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 964 966 964 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IS</sub>
###xml 964 966 964 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>IS</sub></italic>
###xml 1104 1109 1104 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ebos1">[140]</xref>
###xml 1152 1156 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Aref1">[39]</xref>
###xml 1192 1195 1192 1195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1260 1265 1260 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Lorquet1">[141]</xref>
###xml 1267 1272 1267 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gagnon1">[142]</xref>
###xml 1383 1388 1371 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Mitsi1">[124]</xref>
###xml 1390 1395 1378 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Wijelath1">[143]</xref>
###xml 1560 1565 1548 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Taylor1">[144]</xref>
###xml 1001 1006 <span type="species:ncbi:9606">human</span>
###xml 1079 1084 <span type="species:ncbi:9606">human</span>
###xml 1253 1259 <span type="species:ncbi:9606">humans</span>
First of all, an unexpected consequence of introducing sVEGFR1 into the VEGF system was the predicted elevation of plasma VEGF, counter-intuitive to experimental suggestions that sVEGFR1 lowers the availability of circulating VEGF in vivo[8], [16], [18]. Specifically, tuning [sR1]pl up from 0 to 200 pM was accompanied by corresponding increases in [V]pl from 1 to 2 pM (Fig. 3). Analyzing the flow diagrams of the soluble species (Fig. 4), we postulated that sVEGFR1 - as a diffusible decoy receptor of VEGF - was able to facilitate transport of VEGF from the tissue interstitium into blood via either lymph or vascular permeability flow. It is thus conceivable that other soluble receptors of VEGF with interstitial origins could similarly facilitate interstitia-to-blood transport of VEGF - effectively lowering interstitial VEGF and elevating plasma VEGF - allowing us to target a [V]pl of 1.5 pM using lower VEGF-secretion rates and consequentially lower [V]IS. Possible candidates include: (a) human soluble VEGFR2 (160 kDa) - present in significant quantities in healthy human plasma (7-8 ng/mL) [140] and upregulated in acute myeloid leukemia [39]; (b) soluble NRP1 (90 kDa) - a VEGF165-specific antagonist, with documented renal expression in humans [141], [142]; and (c) cellular fibronectin (approximately500 kDa) - with VEGF-affinity sites on its heparin-binding domain [124], [143] and normally present in extracellular matrix but can end up in elevated amounts in plasma upon endothelial dysfunction or vascular injury, such as in pre-eclampsia [144].
###end p 220
###begin p 221
###xml 221 226 217 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Verheul1">[145]</xref>
###xml 266 271 262 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Wijelath1">[143]</xref>
###xml 398 402 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Karumanchi1">[17]</xref>
Furthermore, our model currently has no blood sources of VEGF or sVEGFR1, which would elevate their respective plasma concentrations. Thrombin-activated platelets have been known to release VEGF from their alpha-granules [145], as well as fibronectin-VEGF complexes [143], during wound-healing angiogenesis. Activated peripheral blood mononuclear cells may also be a direct blood source of sVEGFR1 [17]. Intramuscular production of sVEGFR1 was assumed in this model to occur entirely through abluminal endothelial secretion into the interstitium; luminal endothelial secretion into the circulation is a conceivable direct blood source of sVEGFR1 but has yet to be quantitatively documented.
###end p 221
###begin p 222
###xml 154 157 154 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 192 195 192 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">110</sub>
###xml 204 207 204 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">113</sub>
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ferrara1">[95]</xref>
###xml 224 229 224 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Lee1">[146]</xref>
###xml 289 294 289 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Chen1">[147]</xref>
###xml 353 356 353 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 502 507 502 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Tayebjee1">[148]</xref>
###xml 509 514 509 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Signorelli1">[149]</xref>
###xml 580 583 580 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 762 767 762 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ito1">[150]</xref>
Moreover, interstitial proteolytic clearance of soluble or matrix-bound VEGF - e.g., plasmin- and matrix metalloproteinase (MMP)-mediated cleavage of VEGF165 and the respective release of VEGF110 and VEGF113 fragments [95], [146], as well as the intrinsic protein degradation rate of VEGF [147] - was not considered in the current model. Release of VEGF165 from interstitial matrix sites through plasmin/MMP degradation of matrix core proteins was also neglected. Abnormal plasma levels of MMPs in PAD [148], [149] may suggest a role for proteolytic degradation or release of VEGF165 in causing pathological bioavailabilities of VEGF. The recent discovery of possible modulation by MMPs on sVEGFR1's effects on VEGF-VEGFR2 signaling was also not considered here [150].
###end p 222
###begin p 223
###xml 364 369 364 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Maharaj2">[151]</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Guyton1">[93]</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Guyton1">[93]</xref>
Lastly, there may be specialized organs with higher VEGF production rates which, if separately partitioned from our normal compartment, may lessen the burden on skeletal muscle for VEGF production (i.e., VEGF release from tissue to blood, whether via lymph or vascular permeability). Other adult cell sources where VEGF expression has been qualitatively described [151] include: (i) epithelial cells near fenestrated blood vessels (high vascular permeability), e.g., choroid plexus and kidney glomeruli; and (ii) cells adjacent to sinusoidal vessels, e.g., in the liver (which produces half of all lymph formed by the body at rest [93]) and spleen (also the main site of destruction of platelets [93]). In other words, the high interstitial VEGF level predicted in our normal compartment may currently be skewed by lumping skeletal muscle with these organs of higher interstitial VEGF levels.
###end p 223
###begin title 224
Introduction of homodimerized sVEGFR1 and lymphatic drainage did not drastically alter VEGF ligand and receptor distributions in healthy muscle tissues
###end title 224
###begin p 225
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Stefanini1">[59]</xref>
###xml 651 655 <span type="species:ncbi:9913">calf</span>
The model extensions to include homodimeric sVEGFR1 and lymphatic biotransport did not significantly alter our prior steady-state predictions for healthy muscle tissues [54], [59]: that most extracellular VEGF were surface receptor- or matrix-bound; that almost all matrix binding sites were unoccupied by VEGF or sVEGFR1; and that less than a quarter of total receptors on the abluminal surface (8% of VEGFR1, 20% of VEGFR2, and 18% of NRP1) were part of VEGF-bound signaling complexes. In its capacity as a soluble or NRP1-bound trap of VEGF, sVEGFR1 only held small fractions of total interstitial VEGF at control: 0.7% and 3.25% in the normal and calf compartments respectively. However, the present study did not rule out the possibility that monomeric sVEGFR1, in its capacity to heterodimerize with surface VEGFR1 or VEGFR2 monomers, can significantly alter these distributions.
###end p 225
###begin title 226
Significant complexed fractions of VEGF and sVEGFR1 in plasma necessitate re-evaluation of assay specificity
###end title 226
###begin p 227
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Belgore1">[45]</xref>
###xml 257 264 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 577 584 577 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1092 1096 1092 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Belgore1">[45]</xref>
###xml 1433 1438 1433 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Jelkmann1">[152]</xref>
At our simulated healthy control, 77% of total plasma VEGF was sVEGFR1-complexed and 5% of total sVEGFR1 was VEGF-bound, both considerably higher than experimentally measured [45]. The much lower complexed fractions from experimental data may indicate that in vivo, other soluble receptors (e.g., sVEGFR2, sNRP1, plasma fibronectin) can strongly compete with sVEGFR1 as plasma reservoirs for VEGF, or significant quantities of other ligands (e.g., PlGF, VEGF-B) are present to compete with VEGF for sVEGFR1 binding. We propose that the experimental quantification of all major in vivo binding partners for both VEGF and sVEGFR1 from peripheral blood samples to be essential in reconciling the apparent contradiction between predicted and measured VEGF-sVEGFR1 complexed fractions. Alternatively, if our computational predictions correctly suggest that the complexed fractions of VEGF and sVEGFR1 were underestimated experimentally, the implications are that: (1) measurements of free VEGF and free sVEGFR1 should not be taken as stand-ins for circulating (free+bound) VEGF and sVEGFR1 levels [45], and may be insufficient in characterizing disease states; and (2) the variation in complexed fractions may partially account for the well-documented heterogeneity in measurements of plasma VEGF and sVEGFR1. Re-evaluations of assay specificity and protocol standardization for measuring free vs. complexed sVEGFR1, as was done for VEGF [152], may be worthwhile.
###end p 227
###begin title 228
Simulation of VEGF-trapping did not recapitulate sVEGFR1's anti-angiogenic potential
###end title 228
###begin p 229
###xml 129 137 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 139 146 139 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 151 158 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 158 161 158 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Hornig1">[8]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ambati1">[16]</xref>
###xml 169 174 169 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ambati2">[153]</xref>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Luttun1">[18]</xref>
###xml 757 764 757 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g002">Fig. 2A</xref>
###xml 927 934 927 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig. 3A</xref>
Several experimental studies have demonstrated the ability of sVEGFR1 as a ligand sink in lowering the availability of free VEGF in vitro, ex vivo and in vivo[8], [16], [153], or have implicated this ligand-trapping mechanism of sVEGFR1 in the pathogenesis of disease states where inverse changes between VEGF and sVEGFR1 concentrations were generally observed [18]. Thus it was surprising that in our simulations, upregulated expression of either VEGF or sVEGFR1 was not accompanied by significant inverse changes in the systemic levels of the other, as intuitively expected of a straight-forward ligand-trapping behavior. Instead, increasing VEGF production rate from the normal tissue compartment led to drastic increases in sVEGFR1 levels systemically (Fig. 2A). Conversly, when sVEGFR1 production rates were increased, interstitial VEGF only decreased minutely while plasma VEGF counter-intuitively increased drastically (Fig. 3A).
###end p 229
###begin p 230
###xml 1156 1162 1156 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
Based on analyses of the flow balances and distribution profiles at control, we hypothesized that several confounding mechanisms were obscuring the most direct effects of VEGF-trapping by sVEGFR1 (i.e., where upregulated expression of one lowers the availability of the other). In the first scenario where VEGF production was increased, we postulated that increasing VEGF-occupancies of NRP1-coupled complexes actually reduced NRP1-dependent internalization of sVEGFR1, resulting in the non-intuitive increase in systemic levels of free sVEGFR1. In the second scenario where sVEGFR1 production was increased, we postulated that the transendothelial gradients at control were permissive to the trapping of interstitial VEGF by sVEGFR1 and the shuttling of the formed complexes into the blood, whereupon the subsequent dissociation resulted in the non-intuitive increase in plasma free VEGF. In other words, we hypothesized that the net tendency for sVEGFR1-VEGF complex association in the tissue interstitium provided an extra conduit for VEGF to be transported into the tissue (via its complexed form, in addition to simple intravasation of free VEGF; see Fig. 4). Thus an immediate future direction is to perform a thorough mechanistic study to computationally validate these hypotheses, and to search for the conditions under which the VEGF-trapping ability of sVEGFR1 can account for reductions in free VEGF within the same compartment and/or systemically.
###end p 230
###begin p 231
###xml 247 254 247 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig. 3B</xref>
Under the current simulation settings, however, a particularly important result was that the intensities of signaling complex formation (directly proportional to interstitial free VEGF levels) were negligibly affected by sVEGFR1 production rates (Fig. 3B) -computational simulation of just the VEGF-trapping interactions of sVEGFR1 was insufficient to replicate the expected inhibitory function of sVEGFR1 on VEGF-signaling. Counter to prevailing wisdom, simulated increase in production of sVEGFR1 did not lead to significant reduction in intramuscular VEGF-VEGFR2 complex formation. This implication that VEGF-trapping alone may not account for sVEGFR1's anti-angiogenic potential needs to be experimentally validated; while computationally, the next step would be to investigate whether heterodimerization with surface VEGFRs is the key to sVEGFR1's purported contribution in impaired angiogenesis.
###end p 231
###begin p 232
###xml 270 277 270 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Also worth considering are the functional consequences of the counter-intuitive increase in plasma VEGF, at the expense of interstitial VEGF, in response to sVEGFR1 production. While the current model did not simulate luminal endothelial surface VEGFRs, their potential in vivo presence (discussed further below) may suggest the unexpected angiogenic activation of microvasculature in distal tissues by the elevated plasma VEGF as a result of local intramuscular production of sVEGFR1.
###end p 232
###begin title 233
Changing levels of circulating sVEGFR1 may reflect altered tissue expression of surface receptors
###end title 233
###begin p 234
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann3">[54]</xref>
###xml 342 349 342 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g003">Fig. 3B</xref>
###xml 401 404 401 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 475 484 475 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4D,E</xref>
###xml 779 786 779 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g005">Fig. 5A</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g006">6B</xref>
In examining system responses to variations in receptor expression levels and effective ligand-receptor affinities from control values, we confirmed that the introduction of sVEGFR1 into the model did not change previous predictions [54] regarding NRP1 density as a functional "angiogenic switch" of VEGF signaling in skeletal muscle tissue (Fig. 3B). We also demonstrated that the newly proposed VEGF121-NRP1 affinity has a negligible effect on the VEGF signaling profiles (Fig. 4D,E). We further showed that NRP1-dependent internalization of sVEGFR1 can be a major regulator of free sVEGFR1 levels in both interstitia and plasma, both directly (e.g., varying NRP1 densities) and indirectly (e.g., R2/R1 ratio and VEGF-VEGFR1 binding alter the availability of uncoupled NRP1s) (Fig. 5A, 6B). The clinical implication is that pathological levels of plasma sVEGFR1 may not necessarily indicate altered sVEGFR1 production or altered availability of free VEGF, because they may partially reflect altered receptor expression in tissues. This will likely be even more significant when sVEGFR1-heterodimerization with surface receptors are considered.
###end p 234
###begin title 235
Implications of model assumptions for surface receptors
###end title 235
###begin p 236
Here we discuss several assumptions made in the current modeling of surface receptors - (1) static receptor internalization and insertion (conservation of total receptor density), (2) no intracellular trafficking & signaling, (3) no receptor heterodimers, (4) no luminal surface receptors - and in particular, their relevance to the study of sVEGFR1.
###end p 236
###begin p 237
###xml 1061 1067 1061 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g004">Fig. 4</xref>
###xml 1553 1558 1553 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Dougher1">[154]</xref>
###xml 1559 1564 1559 1564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Santos1">[157]</xref>
Firstly, our current implementation assumed constant internalization rates for all receptors and complexes, paired with constant free receptor insertion rates (free VEGFR1, free VEGFR2, free NRP1) defined to conserve the total receptor densities (total VEGFR1, total VEGFR2, total NRP1) at the cell surface. This conservation assumption - i.e., the artificial maintenance of a fixed total receptor density irrespective of the interstitial free VEGF concentration or the degree of receptor activation - had implicitly driven the magnitudes of the internalization flows of soluble species in the tissue compartments. Future investigation is needed to quantify whether the large values of VEGF internalization flows predicted in this study critically depended on the modeled internalization rates and conservation assumptions. Adjustments to the internalization flows of VEGF could significantly alter the secretion flows of VEGF needed to maintain the same steady-state interstitial VEGF concentrations, and in turn significantly shift the tissue flow balance on Fig. 4, such that interstitial VEGF might acquire acute sensitivity to transport parameters, as well as to depletory ligand-trapping by sVEGFR1, against our current findings. There is also justification for beginning investigations into dynamic regulation of receptor internalization, in particular for VEGFR2: VEGF-induction of VEGFR2 internalization has been shown in various studies as receptor tyrosine kinase (RTK) autophosphorylation-, dynamin-, clathrin- and VEGFR1-mediated processes [154]-[157]. Particularly relevant is the latter process of regulation through VEGFR1-VEGFR2 crosstalk, which possibly presents an opportunity for sVEGFR1, as a VEGFR1 competitor, to moderate VEGFR2 activation and internalization.
###end p 237
###begin p 238
###xml 256 261 256 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Mukherjee1">[158]</xref>
###xml 616 621 616 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Ewan1">[159]</xref>
###xml 623 628 623 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Gampel1">[160]</xref>
Secondly, our network of biochemical interactions ended at the level of ligand-receptor binding and complex internalization. Thus far we have used the cell surface densities of VEGF-VEGFR complexes as surrogate markers for "angiogenic signaling potential" [158]; however, there is increasing experimental information on intracellular VEGF signaling, whose contribution can only be assessed with detailed model extensions to keep track of endosomal and caveolar populations of internalized complexes, as well as VEGF-regulated sorting towards degradation, nuclear translocation, or recycling back to the cell surface [159], [160].
###end p 238
###begin p 239
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 38 47 38 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Huang1">[68]</xref>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-MacGabhann8">[70]</xref>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Autiero1">[94]</xref>
###xml 302 309 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Thirdly, there is recent in vitro and in silico evidence supporting significant prevalence of VEGFR1-VEGFR2 heterodimers on endothelial cell surfaces, with signaling properties distinct from those of VEGFR homodimers [68], [70], [94]. Receptor heterodimers were neglected in this model for the lack of in vivo quantification of their relative abundance, and would not have affected current predictions of sVEGFR1's effects on the VEGF system until the focus of study switches to sVEGFR1's alternate role in heterodimerizing with surface VEGFRs.
###end p 239
###begin p 240
###xml 204 209 204 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-QuHong1">[161]</xref>
###xml 349 354 349 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Jelkmann1">[152]</xref>
###xml 695 700 695 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Feng1">[162]</xref>
###xml 883 888 883 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Mukherjee1">[158]</xref>
###xml 1130 1135 1130 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Mukherjee1">[158]</xref>
###xml 1260 1265 1260 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Feng1">[162]</xref>
Lastly, in this study, all receptors were confined to the abluminal endothelial cell surface, in congruence to experimental studies inferring abluminal localization of VEGFRs based on VEGF immunostaining [161] and the common assumption that VEGFRs signaling respond more to local/interstitial VEGF concentrations rather than circulating/plasma VEGF [152]. However, this assumption needs to be thoroughly re-evaluated, in light of recent VEGFR2-immunostaining that localized VEGFR2 equally on luminal and abluminal surfaces of tumor- and adenoVEGF-induced microvascular endothelium, as well as significantly on transendothelial vesiculovaculolar organelles (VVOs) and luminally-attached caveolae [162]. It is unclear whether VEGFR1 and NRP1 also have significant luminal populations, or whether luminal redistribution follows the caveolin-1-dependent internalization unique to VEGFR2 [158]. If luminal expression of VEGFR1 is considered in the future, luminal secretion of sVEGFR1 should be simultaneously investigated as well. Interestingly, a possible luminal bias in Nedd4-stimulated VEGFR2 degradation has also been postulated [158]. Although it is uncertain whether luminal vs. abluminal VEGFR2 have equal signaling potential or similar downstream targets [162], there is urgent need to explore the possibility, especially in the next step of investigating sVEGFR1-heterodimerization with surface receptors, i.e., given the much higher predicted sVEGFR1 concentration in plasma than in the interstitium, the luminal extent of sVEGFR1-VEGFR heterodimerization would be expected to exceed that on the abluminal side.
###end p 240
###begin title 241
sVEGFR1 may attenuate interstitial matrix-bound VEGF gradients by 10% at most
###end title 241
###begin p 242
###xml 678 681 678 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 732 735 732 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 896 902 896 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g007">Fig. 7</xref>
###xml 1204 1211 1204 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1472 1475 1472 1475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1718 1723 1718 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Kappas1">[163]</xref>
###xml 754 758 <span type="species:ncbi:9913">calf</span>
We showed that the densities and affinities of the interstitial matrix binding sites did not affect steady-state predictions of plasma and interstitial levels of the soluble species, nor VEGFR occupancies. We also showed consistently minuscule fractional occupancies of total matrix proteoglycan sites, i.e., VEGF and sVEGFR1 proteins are always hugely outnumbered by glycosaminoglycan binding-sites in the interstitial matrix. To the extent that the present study focuses on sVEGFR1's effect on the formation of surface VEGF signaling complexes, the uncertainties in the characterization of matrix sites are not of concern. However, the absolute quantities of matrix-bound VEGF165 and sVEGFR1 - comprising 36% and 72% of total VEGF165 in the normal and calf tissues respectively, as well as 97% of total sVEGFR1 in either tissue - were greatly sensitive to matrix site densities and affinities (Fig. 7). The sizes of matrix-bound reservoirs of VEGF and sVEGFR1 may affect the time course of dynamic concentration changes in free VEGF, free sVEGFR1 or surface signaling complexes. Although the compartmental model did not include the spatial resolution needed to examine interstitial VEGF gradients, the in vivo distribution of matrix sites between the ECM and BMs could affect spatial morphogenic gradients that guide sprouting angiogenesis. In fact, a recent study attributed the ability of sVEGFR1 in rescuing the branching morphogenesis of developing vessels in VEGFR1-/- mutant embryonic cell cultures to sVEGFR1's role as a diffusible VEGF sink: that by diffusing away from the cell surface, it is able to alter the interstitial VEGF gradients as presented to endothelial tip cell filopodia of sprouting vessels [163].
###end p 242
###begin p 243
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M&#183;V&#183;sR<sub>1</sub></italic>
###xml 655 662 643 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005108.s002">Fig. S2</xref>
###xml 911 912 887 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 910 912 886 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 913 916 889 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M&#183;V</italic>
###xml 919 920 895 896 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 917 920 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR<sub>1</sub></italic>
###xml 936 937 900 901 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 935 937 899 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>d</sub></italic>
###xml 938 939 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 942 943 906 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 940 943 904 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sR<sub>1</sub></italic>
The present model was not able to directly address the modulating effects of sVEGFR1 on the matrix-bound VEGF gradients, because we did not model the subsequent binding of sVEGFR1 to matrix-bound VEGF (forming M.V.sR1), due to insufficient experimental knowledge about its hypothetical binding configuration - e.g., whether the sVEGFR1-binding domain of VEGF is still exposed after matrix-association, and whether subsequent sVEGFR1 binding can effectively mask or protect the matrix-bound VEGF from participating in capillary sprout guidance. However, considering that the ratio of interstitial free sVEGFR1 to matrix-bound VEGF was approximately1:12.5 (Fig. S2), even the hypothetical recruitment of all available sVEGFR1 would only attenuate the matrix gradient of VEGF by approximately10% (non-equilibrated). Ignoring all other compensating interactions and processes in the molecular system, and assuming Kd(M.V,sR1) approximatelyKd(V,sR1), a simple equilibrium approximation of sVEGFR1 attenuation of matrix-bound VEGF would be approximately7.5%:
###end p 243
###begin title 244
Physiological variations in transport rates affected the stability and reliability of plasma VEGF and sVEGFR1 as diagnostic markers
###end title 244
###begin p 245
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 176 178 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 258 260 258 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 268 270 268 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 268 270 268 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 368 375 368 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9B</xref>
###xml 411 418 <span type="species:ncbi:9606">patient</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
We showed that both free VEGF and free sVEGFR1 levels in plasma varied significantly over the tested physiological ranges of transport parameters: e.g., the activity-dependent kL changes typically experienced during an active day led to fluctuations in [sR1]pl and [V]pl of up to 76 pM and 1.65 pM about their healthy control levels of 100 pM and 1.5 pM respectively (Fig. 9B). This indicated that normal inter-patient variations in permeability and lymph flow rates - as dependent on patients' physical activity levels (sedentary vs. active lifestyle), posture during blood sampling, etc. - may contribute to the physiological heterogeneity in the clinical measurements of plasma VEGF and sVEGFR1 among healthy control cohorts. Corrections for these factors may yield more stable and consistent healthy benchmarks for the use of plasma VEGF or sVEGFR1 as diagnostic markers.
###end p 245
###begin p 246
###xml 314 321 314 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
On the other hand, interstitial VEGF levels remained unchanged over the physiological variations in transport rates, because the predicted secretion and internalization flows of VEGF dominated over all its inter-compartmental transport flows. These relative flow magnitudes have not been experimentally validated; in vivo quantification of VEGF secretion rates would be invaluable to assess our targeted secretion rates which were highly dependent on the chosen initial configurations of internalizable receptors. When interstitial VEGF is unresponsive to changes in transport rates, so is the predicted formation of signaling complexes on the tissue endothelia. The significance here is that the physiological variation in transport rates offers a case example where the common circulating angiogenic markers become unreliable, i.e., apparent changes in free VEGF or sVEGFR1 levels in the plasma do not correlate with changes in the actual angiogenic signaling potential in the tissues. However, considering the significant sensitivity of interstitial sVEGFR1 to transport rates, we cannot rule out the possibility that once sVEGFR1-heterodimerization with surface VEGFRs is in place, that transport rates may indeed affect the formation of signaling complexes in muscles.
###end p 246
###begin p 247
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 52 54 52 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 255 257 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 370 371 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 406 408 406 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 406 408 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 458 460 458 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 458 460 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 462 469 462 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9B</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Bailey1">[49]</xref>
###xml 577 579 565 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 577 579 565 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 679 681 643 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 679 681 643 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 747 748 699 700 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 746 748 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 774 776 726 728 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 774 776 726 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 862 863 814 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 861 863 813 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 886 888 838 840 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pl</sub>
###xml 886 888 838 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>pl</sub></italic>
###xml 1197 1203 1149 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1203 1207 1155 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005108-Bailey1">[49]</xref>
###xml 1321 1322 1273 1274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1320 1322 1272 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 1381 1388 1333 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005108-g009">Fig. 9B</xref>
###xml 1837 1838 1789 1790 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1836 1838 1788 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 487 492 <span type="species:ncbi:9606">human</span>
###xml 1509 1517 <span type="species:ncbi:9606">patients</span>
###xml 1889 1897 <span type="species:ncbi:9606">patients</span>
As a first assessment of whether activity-dependent kL can account for the surge in plasma sVEGFR1 observed after acute exercise in healthy individuals, simulations were performed without concurrent exercise-induced changes to sVEGFR1 or VEGF production, kP, or receptor expression. Immediately after the onset of exercise, independent simulation of activity-dependent kL predicted that an elevation in [V]pl preceded the larger but slower elevation in [sR1]pl (Fig. 9B). In contrast, a human study [49] showed acute exercise to cause a fast approximately50% elevation in [sR1]pl (peaking approximately0.5 h after exercise) which preceded a temporary approximately50% drop in [V]pl (lowest at approximately2 h after exercise). Thus our simulated kL-induced increase in [sR1]pl roughly matched that in the exercise study in magnitude but not in speed; while our kL-induced changes in [V]pl was in opposite direction to those in the exercise study. This may suggest that hypoxia-induced secretion of sVEGFR1 (as opposed to lymphatic drainage of sVEFR1) is indeed the faster and major source of elevated plasma sVEGFR1 in exercise; but our simulations were unable to confirm the conclusion by Bailey et al.[49] that VEGF trapping by the surge of sVEGFR1 had caused the drop in plasma VEGF. In any case, the fact that lower kL's associated with inactivity led to lower plasma sVEGFR1 (Fig. 9B) supported the possibilities that: (i) PAD-associated immobility may contribute to the lower plasma sVEGFR1 seen in PAD patients, although it remains to be experimentally validated whether a corresponding accumulation of interstitial sVEGFR1 and consequential impairment of muscle angiogenesis would occur; and that (ii) exercise rehabilitation may partly reverse the pathological levels of circulating angiogenic markers through activity-induced kL, thereby ameliorating the angiogenic state in PAD patients. If future considerations of sVEGFR1 heterodimerization with surface VEGFR can establish a link between transport-dependent fluctuations in sVEGFR1 levels and angiogenic signalling intensity, the clinical implications would be significant: e.g., therapeutic delivery of VEGF-C/D (the VEGF family members involved in lymphangiogenesis) alongside VEGF-A to ischemic tissues could be explored for synergistic effects of increased lymph flow on the angiogenic efficacy of VEGF-A.
###end p 247
###begin p 248
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 122 124 122 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
###xml 288 289 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 287 289 287 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>L</sub></italic>
###xml 295 296 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</sub>
###xml 294 296 294 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k<sub>P</sub></italic>
Limitations in model assumptions that can affect the above conclusions include: underestimations of the effective control kL and kP due to lumping of highly-perfused organs with skeletal muscle tissue in the normal compartment; overestimation of whole-body exercise-induced increases in kL and kP as non-skeletal muscle organs (e.g., liver) should maintain resting rates; and misestimation of clearance rates of sVEGFR1 and sVEGFR1-VEGF from the plasma half-lives of synthetic soluble VEGF-traps.
###end p 248
###begin title 249
Future directions
###end title 249
###begin p 250
###xml 462 470 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 475 482 475 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
The immediate task is to perform a computational mechanistic study to investigate why simulations of VEGF-trapping by sVEGFR1 did not demonstrate any purported anti-angiogenic effects: Does interstitium-to-blood shuttling of VEGF-sVEGFR1 complexes explain the apparent absence of local reductions in free VEGF upon increased interstitial sVEGFR1 production? Are there alternate conditions under which sVEGFR1, as a VEGF sink, can indeed dampen VEGF signaling as in vitro and ex vivo experiments have suggested?
###end p 250
###begin p 251
sVEGFR1-heterodimerization of surface VEGFRs is expected to present an alternative way for sVEGFR1 to modulate VEGF signal transduction even when interstitial free VEGF levels remain high, by effectively reducing the availability of functional endothelial surface VEGFR dimers for VEGF activation, assuming that VEGFR heterodimers with sVEGFR1 cannot signal. These effects are likely to be heavily determined by the proportionality of sVEGFR-VEGFR1 vs. sVEGFR-VEGFR2 binding; that is, any bias in the coupling of sVEGFR1 to VEGFR1 or VEGFR2 would tilt VEGF-activated signaling in the direction of the other receptor. Thus the next step would be to extend the model to quantify the contribution of this heterodimerization mechanism to sVEGFR1's anti-angiogenic potential.
###end p 251
###begin p 252
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005108-t012">Table 12</xref>
###xml 389 394 <span type="species:ncbi:9606">human</span>
Table 12 compares our significant computational predictions with current experimental data; future experiments to address the proposed sources of discrepancies are recommended. With future availability of experimental validation to address the current limitations in model assumptions, the multi-compartmental model put forth in this study can be more finely tuned to accurately represent human subjects - healthy or diseased - to serve as a computational platform for design and testing of integrative pro-angiogenic therapies.
###end p 252
###begin title 253
Comparing Computational Predictions with Experimental Data.
###end title 253
###begin title 254
Supporting Information
###end title 254
###begin p 255
Healthy Subject: Complete Molecular Distribution Analysis for Varying VEGF Secretion Rates. (A) Free VEGF and free sVEGFR1 distributions. (B) Total sVEGFR1 distribution. (C) Total VEGF121 distribution. (D) Total VEGF165 distribution. (E) Extracellular matrix binding site occupancies. (F) Endothelial basement membrane binding site occupancies. (G) Parenchymal basement membrane binding site occupancies. (H) VEGFR1 occupancies. (I) VEGFR2 occupancies. (J) NRP1 occupancies. (K) VEGF-bound VEGFR complexes.
###end p 255
###begin p 256
(0.15 MB PDF)
###end p 256
###begin p 257
Click here for additional data file.
###end p 257
###begin p 258
Healthy Subject: Complete Molecular Distribution Analysis for Varying sVEGFR1 Secretion Rates. (A) Free VEGF and free sVEGFR1 distributions. (B) Total sVEGFR1 distribution. (C) Total VEGF121 distribution. (D) Total VEGF165 distribution. (E) Extracellular matrix binding site occupancies. (F) Endothelial basement membrane binding site occupancies. (G) Parenchymal basement membrane binding site occupancies. (H) VEGFR1 occupancies. (I) VEGFR2 occupancies. (J) NRP1 occupancies. (K) VEGF-bound VEGFR complexes.
###end p 258
###begin p 259
(0.15 MB PDF)
###end p 259
###begin p 260
Click here for additional data file.
###end p 260
###begin p 261
We thank Dr. Brian H. Annex and Dr. Christopher D. Kontos for their experimental data, clinical insights and helpful discussions.
###end p 261
###begin title 262
References
###end title 262
###begin article-title 263
Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine.
###end article-title 263
###begin article-title 264
Angiogenesis in cancer and other diseases.
###end article-title 264
###begin article-title 265
Systems biology of vascular endothelial growth factors.
###end article-title 265
###begin article-title 266
###xml 58 63 <span type="species:ncbi:9606">human</span>
VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise.
###end article-title 266
###begin article-title 267
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Differential expression of VEGF isoforms in mouse during development and in the adult.
###end article-title 267
###begin article-title 268
Therapeutic angiogenesis in peripheral arterial disease: Can biotechnology produce an effective collateral circulation?
###end article-title 268
###begin article-title 269
Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.
###end article-title 269
###begin article-title 270
Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids.
###end article-title 270
###begin article-title 271
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.
###end article-title 271
###begin article-title 272
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
###end article-title 272
###begin article-title 273
VEGF receptor signalling - in control of vascular function.
###end article-title 273
###begin article-title 274
Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1.
###end article-title 274
###begin article-title 275
Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.
###end article-title 275
###begin article-title 276
The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1.
###end article-title 276
###begin article-title 277
The role of VEGF receptors in angiogenesis; complex partnerships.
###end article-title 277
###begin article-title 278
Corneal avascularity is due to soluble VEGF receptor-1.
###end article-title 278
###begin article-title 279
###xml 41 48 <span type="species:ncbi:9031">chicken</span>
Hypoxia and sFlt-1 in preeclampsia: The "chicken-and-egg" question.
###end article-title 279
###begin article-title 280
Soluble VEGF receptor Flt1: The elusive preeclampsia factor discovered?
###end article-title 280
###begin article-title 281
Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: Differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
###end article-title 281
###begin article-title 282
Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.
###end article-title 282
###begin article-title 283
Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors.
###end article-title 283
###begin article-title 284
###xml 120 124 <span type="species:ncbi:10090">mice</span>
Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice.
###end article-title 284
###begin article-title 285
Fabrication of endothelialized tube in collagen gel as starting point for self-developing capillary-like network to construct three-dimensional organs in vitro.
###end article-title 285
###begin article-title 286
###xml 38 62 <span type="species:ncbi:10804">adeno-associated virus 2</span>
Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
###end article-title 286
###begin article-title 287
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
###end article-title 287
###begin article-title 288
###xml 89 98 <span type="species:ncbi:10090">nude mice</span>
Soluble fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice.
###end article-title 288
###begin article-title 289
###xml 121 126 <span type="species:ncbi:9606">human</span>
Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.
###end article-title 289
###begin article-title 290
Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble flt-1.
###end article-title 290
###begin article-title 291
Transduction of soluble flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer.
###end article-title 291
###begin article-title 292
sFlt-1 gene therapy of follicular thyroid carcinoma.
###end article-title 292
###begin article-title 293
###xml 51 55 <span type="species:ncbi:10116">rats</span>
Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer.
###end article-title 293
###begin article-title 294
Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier.
###end article-title 294
###begin article-title 295
###xml 86 92 <span type="species:ncbi:10090">murine</span>
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis.
###end article-title 295
###begin article-title 296
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis.
###end article-title 296
###begin article-title 297
###xml 65 71 <span type="species:ncbi:10090">murine</span>
Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis.
###end article-title 297
###begin article-title 298
Postischemic gene transfer of soluble flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
###end article-title 298
###begin article-title 299
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
###end article-title 299
###begin article-title 300
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.
###end article-title 300
###begin article-title 301
###xml 60 67 <span type="species:ncbi:9606">patient</span>
Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
###end article-title 301
###begin article-title 302
A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis.
###end article-title 302
###begin article-title 303
Soluble flt-1 as a diagnostic marker of pre-eclampsia.
###end article-title 303
###begin article-title 304
###xml 58 63 <span type="species:ncbi:9606">women</span>
Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery doppler velocimetry.
###end article-title 304
###begin article-title 305
###xml 138 146 <span type="species:ncbi:9606">patients</span>
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
###end article-title 305
###begin article-title 306
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor and its receptor, flt-l, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes.
###end article-title 306
###begin article-title 307
Measurement of free and complexed soluble vascular endothelial growth factor receptor, flt-1, in fluid samples: Development and application of two new immunoassays.
###end article-title 307
###begin article-title 308
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: A link between angiogenesis and thrombogenesis?
###end article-title 308
###begin article-title 309
Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von willebrand factor in glaucoma.
###end article-title 309
###begin article-title 310
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment.
###end article-title 310
###begin article-title 311
Exercise increases soluble vascular endothelial growth factor receptor-1 (sFlt-1) in circulation of healthy volunteers.
###end article-title 311
###begin article-title 312
Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: A substudy of the anglo-scandinavian cardiac outcomes trial (ASCOT).
###end article-title 312
###begin article-title 313
Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy.
###end article-title 313
###begin article-title 314
Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.
###end article-title 314
###begin article-title 315
Mapping the theories of preeclampsia and the role of angiogenic factors: A systematic review.
###end article-title 315
###begin article-title 316
###xml 102 107 <span type="species:ncbi:9606">human</span>
Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: A computational model of human skeletal muscle.
###end article-title 316
###begin article-title 317
Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy.
###end article-title 317
###begin article-title 318
VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle.
###end article-title 318
###begin article-title 319
Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease.
###end article-title 319
###begin article-title 320
Skeletal muscle VEGF gradients in peripheral arterial disease: Simulations of rest and exercise.
###end article-title 320
###begin article-title 321
A compartment model of VEGF distribution in blood, healthy and diseased tissues.
###end article-title 321
###begin article-title 322
###xml 37 42 <span type="species:ncbi:9606">human</span>
Lymphangiogenesis in development and human disease.
###end article-title 322
###begin article-title 323
###xml 34 39 <span type="species:ncbi:9606">human</span>
Lymph flow dynamics in exercising human skeletal muscle as detected by scintography.
###end article-title 323
###begin article-title 324
Interstitial fluid volume: Local regulatory mechanisms.
###end article-title 324
###begin article-title 325
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Current medical therapies for patients with peripheral arterial disease: A critical review.
###end article-title 325
###begin article-title 326
###xml 23 28 <span type="species:ncbi:9606">human</span>
Albumin clearance from human skeletal muscle during prolonged steady-state running.
###end article-title 326
###begin article-title 327
Inter-society consensus for the management of peripheral arterial disease.
###end article-title 327
###begin article-title 328
Roles for VEGF in the adult.
###end article-title 328
###begin article-title 329
Neuropilin-1 affects VEGF binding to VEGF receptors on endothelial cells in vivo: Predictions from a computational model.
###end article-title 329
###begin article-title 330
Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers.
###end article-title 330
###begin article-title 331
Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer.
###end article-title 331
###begin article-title 332
Dimerization of VEGF receptors and implications for signal transduction: A computational study.
###end article-title 332
###begin article-title 333
Porosity, tortuosity, and available volume fraction.
###end article-title 333
###begin article-title 334
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 32 36 <span type="species:ncbi:9913">calf</span>
Volumetric measurement of human calf muscle from magnetic resonance imaging.
###end article-title 334
###begin article-title 335
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Muscle fiber characteristics in patients with peripheral arterial disease.
###end article-title 335
###begin article-title 336
Myonuclear domains in muscle adaptation and disease.
###end article-title 336
###begin article-title 337
###xml 42 47 <span type="species:ncbi:9606">human</span>
Myonuclear domain and myosin phenotype in human soleus after bed rest with or without loading.
###end article-title 337
###begin article-title 338
Skeletal muscle capillaries in nondiabetics. A quantitative analysis.
###end article-title 338
###begin article-title 339
Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells.
###end article-title 339
###begin article-title 340
###xml 74 77 <span type="species:ncbi:9615">dog</span>
Correlation of endothelial cell shape and wall shear stress in a stenosed dog aorta.
###end article-title 340
###begin article-title 341
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Arteriolization of capillaries and FGF-2 upregulation in skeletal muscles of patients with chronic peripheral arterial disease.
###end article-title 341
###begin article-title 342
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients.
###end article-title 342
###begin article-title 343
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Muscle capillary basement membrane width in patients with vacor-induced diabetes mellitus.
###end article-title 343
###begin article-title 344
Evaluation of muscle capillary basement membrane in inflammatory myopathy. A morphometric ultrastructural study.
###end article-title 344
###begin article-title 345
Flow through interstitium and other fibrous matrices.
###end article-title 345
###begin article-title 346
###xml 50 56 <span type="species:ncbi:9606">humans</span>
The pharmacokinetics of the interstitial space in humans.
###end article-title 346
###begin article-title 347
Available space and extracellular transport of macromolecules: Effects of pore size and connectedness.
###end article-title 347
###begin article-title 348
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability.
###end article-title 348
###begin article-title 349
###xml 41 46 <span type="species:ncbi:9606">human</span>
Density and hydration of fresh and fixed human skeletal muscle.
###end article-title 349
###begin article-title 350
###xml 53 56 <span type="species:ncbi:9606">man</span>
Capillary supply of the quadriceps femoris muscle of man: Adaptive response to exercise.
###end article-title 350
###begin article-title 351
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Capillary changes in skeletal muscle of patients with essential hypertension.
###end article-title 351
###begin article-title 352
Basement membranes: Structure, assembly and role in tumour angiogenesis.
###end article-title 352
###begin article-title 353
Imaging of angiogenesis in inflamed airways and tumors: Newly formed blood vessels are not alike and may be wildly abnormal: Parker B. francis lecture.
###end article-title 353
###begin article-title 354
Endurance exercise training decreases capillary basement membrane width in older nondiabetic and diabetic adults.
###end article-title 354
###begin article-title 355
Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
###end article-title 355
###begin article-title 356
The biology of vascular endothelial growth factor.
###end article-title 356
###begin article-title 357
###xml 74 79 <span type="species:ncbi:9606">human</span>
Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects.
###end article-title 357
###begin article-title 358
###xml 65 70 <span type="species:ncbi:9606">human</span>
Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites.
###end article-title 358
###begin article-title 359
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
###end article-title 359
###begin article-title 360
###xml 3 7 <span type="species:ncbi:10090">mice</span>
In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia.
###end article-title 360
###begin article-title 361
Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain.
###end article-title 361
###begin article-title 362
###xml 56 61 <span type="species:ncbi:9606">human</span>
Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.
###end article-title 362
###begin article-title 363
VEGF signalling: Integration and multi-tasking in endothelial cell biology.
###end article-title 363
###begin article-title 364
The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.
###end article-title 364
###begin article-title 365
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.
###end article-title 365
###begin article-title 366
Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting.
###end article-title 366
###begin article-title 367
Alternative splicing in angiogenesis: The vascular endothelial growth factor paradigm.
###end article-title 367
###begin article-title 368
A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors.
###end article-title 368
###begin article-title 369
Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library.
###end article-title 369
###begin article-title 370
Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.
###end article-title 370
###begin article-title 371
###xml 76 80 <span type="species:ncbi:9615">dogs</span>
Transport of large molecules from plasma to interstitial fluid and lymph in dogs.
###end article-title 371
###begin article-title 372
Comparison of the permeability surface product (PS) of the blood capillary wall in skeletal muscle tissue of various species and in vitro porous membranes using hydrophilic drugs.
###end article-title 372
###begin article-title 373
Microcirculatory compensation to progressive atherosclerotic disease.
###end article-title 373
###begin article-title 374
Vascular recruitment in skeletal muscle during exercise and hyperinsulinemia assessed by contrast ultrasound.
###end article-title 374
###begin article-title 375
Last word on point:Counterpoint: There is/is not capillary recruitment in active skeletal muscle during exercise.
###end article-title 375
###begin article-title 376
Effects of acute exercise, exercise training, and diabetes on the expression of lymphangiogenic growth factors and lymphatic vessels in skeletal muscle.
###end article-title 376
###begin article-title 377
###xml 4 7 <span type="species:ncbi:9606">man</span>
###xml 102 107 <span type="species:ncbi:9606">human</span>
VIP-man: An image-based whole-body adult male model constructed from color photographs of the visible human project for multi-particle monte carlo calculations.
###end article-title 377
###begin article-title 378
###xml 44 47 <span type="species:ncbi:9606">men</span>
Flow and composition of leg lymph in normal men during venous stasis, muscular activity and local hyperthermia.
###end article-title 378
###begin article-title 379
Lymph flow and protein in the normal male leg during lying, getting up, and walking.
###end article-title 379
###begin article-title 380
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 140 146 <span type="species:ncbi:9606">humans</span>
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
###end article-title 380
###begin article-title 381
VEGF-trap: A VEGF blocker with potent antitumor effects.
###end article-title 381
###begin article-title 382
###xml 95 103 <span type="species:ncbi:9606">patients</span>
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
###end article-title 382
###begin article-title 383
VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.
###end article-title 383
###begin article-title 384
Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites.
###end article-title 384
###begin article-title 385
Interactions between heparan sulfate and proteins: The concept of specificity.
###end article-title 385
###begin article-title 386
###xml 42 47 <span type="species:ncbi:9606">human</span>
Protein-bound heparin/heparan sulfates in human adult and umbilical cord plasma.
###end article-title 386
###begin article-title 387
Physiology of fibronectin.
###end article-title 387
###begin article-title 388
###xml 103 107 <span type="species:ncbi:10090">mice</span>
Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin-induced diabetic mice.
###end article-title 388
###begin article-title 389
Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma.
###end article-title 389
###begin article-title 390
Basement membrane proteoglycans: From cellar to ceiling.
###end article-title 390
###begin article-title 391
Heparan sulfates in skeletal muscle development and physiology.
###end article-title 391
###begin article-title 392
Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins.
###end article-title 392
###begin article-title 393
###xml 76 79 <span type="species:ncbi:9606">men</span>
Lower skeletal muscle capillarization and VEGF expression in aged vs. young men.
###end article-title 393
###begin article-title 394
###xml 127 132 <span type="species:ncbi:9606">women</span>
Lower capillarization, VEGF protein, and VEGF mRNA response to acute exercise in the vastus lateralis muscle of aged vs. young women.
###end article-title 394
###begin article-title 395
###xml 109 112 <span type="species:ncbi:9606">men</span>
No difference in the skeletal muscle angiogenic response to aerobic exercise training between young and aged men.
###end article-title 395
###begin article-title 396
###xml 116 121 <span type="species:ncbi:9606">human</span>
Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium.
###end article-title 396
###begin article-title 397
###xml 80 83 <span type="species:ncbi:9606">men</span>
Circulating plasma VEGF response to exercise in sedentary and endurance-trained men.
###end article-title 397
###begin article-title 398
Acute resistance exercise increases skeletal muscle angiogenic growth factor expression.
###end article-title 398
###begin article-title 399
###xml 22 27 <span type="species:ncbi:9606">human</span>
Microdialysis: Use in human exercise studies.
###end article-title 399
###begin article-title 400
###xml 96 101 <span type="species:ncbi:10090">mouse</span>
###xml 106 111 <span type="species:ncbi:9606">human</span>
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
###end article-title 400
###begin article-title 401
Implication of soluble receptors of VEGF, sVEGFR-1 and sVEGFR-2, in angiogenesis.
###end article-title 401
###begin article-title 402
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity.
###end article-title 402
###begin article-title 403
Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: Enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism.
###end article-title 403
###begin article-title 404
High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone.
###end article-title 404
###begin article-title 405
Platelets take up the monoclonal antibody bevacizumab.
###end article-title 405
###begin article-title 406
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.
###end article-title 406
###begin article-title 407
Integrated approach to designing growth factor delivery systems.
###end article-title 407
###begin article-title 408
Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: Relationship to disease severity.
###end article-title 408
###begin article-title 409
Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease.
###end article-title 409
###begin article-title 410
Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells.
###end article-title 410
###begin article-title 411
Vascular endothelial growth factor localization in the adult.
###end article-title 411
###begin article-title 412
Pitfalls in the measurement of circulating vascular endothelial growth factor.
###end article-title 412
###begin article-title 413
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier.
###end article-title 413
###begin article-title 414
Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization.
###end article-title 414
###begin article-title 415
Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase.
###end article-title 415
###begin article-title 416
Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments.
###end article-title 416
###begin article-title 417
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing.
###end article-title 417
###begin article-title 418
Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function.
###end article-title 418
###begin article-title 419
Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells.
###end article-title 419
###begin article-title 420
VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment.
###end article-title 420
###begin article-title 421
Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium.
###end article-title 421
###begin article-title 422
###xml 145 150 <span type="species:ncbi:10090">mouse</span>
Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors.
###end article-title 422
###begin article-title 423
The VEGF receptor flt-1 spatially modulates flk-1 signaling and blood vessel branching.
###end article-title 423
###begin article-title 424
###xml 45 48 <span type="species:ncbi:9606">men</span>
###xml 53 58 <span type="species:ncbi:9606">women</span>
Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr.
###end article-title 424
###begin article-title 425
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Safety and pharmacokinetics of intravenous VEGF trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors.
###end article-title 425
###begin article-title 426
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.
###end article-title 426
###begin article-title 427
###xml 124 129 <span type="species:ncbi:9606">human</span>
Serial effects of high-resistance and prolonged endurance training on na+-K+ pump concentration and enzymatic activities in human vastus lateralis.
###end article-title 427
###begin p 428
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 428
###begin p 429
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by: the National Institutes of Health (NIH) grants, RO1 HL079653 and R33 HL087351; a Natural Sciences and Engineering Research Council of Canada postgraduate PGS-M scholarship (FTHW); and an NIH training grant, T32 HL7284 (FMG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 429

